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ABSTRACT 
 
Cell entry by paramyxoviruses requires fusion between viral and cellular 
membranes. Paramyxovirus infection also gives rise to the formation of 
multinuclear, fused cells (syncytia).  Both types of fusion are mediated by the 
viral fusion (F) protein, which requires proteolytic processing at a basic 
cleavage site in order to be active for fusion.  In common with most 
paramyxoviruses, fusion mediated by Sendai virus F protein (F_SeV) requires 
co-expression of the homologous attachment (HN, haemagglutinin-
neuraminidase) protein, which binds to cell surface sialic acid receptors.  In 
contrast, respiratory syncytial virus fusion protein (F_RSV) is capable of fusing 
membranes in the absence of the viral attachment (G) glycoprotein.  Moreover, 
F_RSV is unique among paramyxovirus fusion proteins since F_RSV 
possesses two multibasic cleavage sites, which are separated by an intervening 
region of 27 amino acids.  We constructed a series of chimeric F_SeV mutants 
by insertion of one or both F_RSV cleavage sites and various regions of pep27 
into F_SeV.  Insertion of both F_RSV cleavage sites in F_SeV led to increased 
cell-cell fusion of transfected cells and a reduced dependency on the HN 
attachment protein for syncytia formation.  In light of the results in transfected 
cells, we rescued recombinant Sendai viruses (rSeV) expressing mutant F 
proteins containing one or both F_RSV cleavage sites.  All cleavage site mutant 
rSeV displayed reduced thermostability, with double cleavage site mutants 
exhibiting a hyperfusogenic phenotype in infected cells.  Furthermore, double 
cleavage site mutant rSeV were less dependent on the interaction of HN with 
sialic acid for infection, thus mimicking the unique ability of RSV to fuse and 
infect cells in the absence of a separate attachment protein.   Therefore, these 
results support the hypothesis that the presence of two multibasic cleavage 
sites represents a strategy to regulate activation of a paramyxovirus F protein 
for cell-cell fusion in the absence of an attachment protein. 
Abstract 
 
16 
RESUMEN 
 
Los paramixovirus requieren para su entrada en la célula diana la fusión entre 
las membranas de la célula y el virus.  La infección por paramixovirus también 
produce la fusión de células entre sí, dando lugar a células grandes 
multinucleadas (sincitios).  Ambos tipos de fusión son mediados por la proteína 
viral de fusión (F), que para su activación requiere que se produzca un 
procesamiento proteolítico en un sitio de corte de carácter básico. Al igual que 
la mayoría de los paramixovirus, la fusión mediada por la proteína de fusión del 
virus Sendai (F_SeV) requiere coexpresión de la proteína de unión al receptor 
(HN), que se une a residuos de ácido siálico en la superficie celular.  Por el 
contrario, la proteína de fusión del virus respiratorio sincitial (F_RSV) puede 
producir fusión de membranas en ausencia de la glicoproteína viral de unión al 
receptor (G).  La proteína de fusión F_RSV es única entre los paramixovirus, ya 
que posee dos sitios de corte multibásicos, separados por una región de 27 
aminoácidos (pep27).  En este trabajo se han construido una serie de mutantes 
quiméricos de F_SeV en los que se han insertado uno o los dos sitios de corte 
de F_RSV y diversas regiones del pep27.  La inserción de los dos sitios de 
corte de F_RSV en F_SeV promovió un aumento de la fusión de células 
transfectadas y una reducción en la dependencia de la proteína de unión HN 
para la formación de sincitios.  A la vista de los resultados obtenidos en células 
transfectadas, se procedió al rescate de virus Sendai recombinantes (rSeV), 
que expresan proteínas F mutantes que tienen uno o los dos sitios de corte de 
F_RSV.  Todos los rSeV con sitios de corte mutados tuvieron una estabilidad 
térmica reducida, y los mutantes con el doble sitio de procesamiento mostraron 
un fenotipo hiperfusogénico en células infectadas.  Además, los mutantes rSeV 
con dos sitios de corte mostraron menor dependencia de la interacción de HN 
con ácido siálico para la infección, imitando así la capacidad específica de RSV 
para fusionar e infectar células en ausencia de la proteína de unión al receptor.  
Por lo tanto, estos resultados sugieren que la presencia de dos sitios de corte 
mutlibásicos representa una estrategia para regular la activación de una 
proteína de fusión de paramixovirus en ausencia de la proteína de unión al 
receptor.
  
 
 
 
 
 
 
                  
1. INTRODUCTION  
  
Introduction 
 
19 
1.   INTRODUCTION 
 
1.1  Classification of paramyxoviruses 
 
The Paramyxoviridae family of enveloped, negative-strand RNA viruses 
(Mononegavirales) includes highly prevalent human viruses (measles, 
respiratory syncytial virus), economically important animal viruses (Newcastle 
disease virus, rinderpest virus), and the recently identified Hendra and Nipah 
viruses that cause fatal disease.  Paramyxoviruses are subdivided into two 
subfamilies: the Paramyxovirinae and the Pneumovirinae (Collins and Crowe 
2007).  Paramyxovirinae and Pneumovirinae can be distinguished 
morphologically by differences in the size and shape of the nucleocapsids 
(Bhella et al., 2002), and by major differences both in the number of encoded 
proteins and the nature of the attachment protein (Fig. 1.1).   
                 
Sendai virus (SeV) and human respiratory syncytial virus (RSV) are 
representative members of the Paramyxovirinae and Pneumovirinae 
subfamilies, respectively.  RSV was first isolated in 1956 from a laboratory 
chimpanzee with a common cold-like illness (Blount et al., 1956), and was 
subsequently recovered from two children with respiratory illness.  Serological 
studies confirmed that infection of children was common (Chanock et al., 1957), 
and RSV is now recognised as the leading cause of serious paediatric 
respiratory tract disease worldwide (Nair et al., 2010).  In addition, RSV may 
also cause serious disease in the elderly and the severely immunosuppressed 
(Falsey et al., 2005).  While RSV is considered an important pathogen for 
vaccine development, vaccination of infants with formalin-inactivated RSV (FI-
RSV) in the 1960s was poorly protective (Kim et al., 1969).  Furthermore, FI-
RSV vaccination was associated with increased severity of disease on 
subsequent natural infection with RSV (Openshaw et al., 2001).  Natural RSV 
infection does not produce lasting protective immunity, and repeated infections 
throughout life are common.   Therefore, advances in the knowledge of the 
biology of RSV remain crucial for the future development of licensed vaccines 
and antiviral agents.   
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Sendai virus, also known as murine parainfluenza virus type 1, is responsible 
for a highly transmissible respiratory tract infection in mice, hamsters and rats.  
Sendai virus is frequently studied as an archetypal representative of the entire 
Paramyxoviridae family in order to elucidate the molecular and biological 
properties of the paramyxoviruses (Faisca and Desmecht 2007).  Scientific 
interest in SeV has also increased in recent years due to its potential value as a 
vector for gene transfer (Kinoh and Inoue 2008).       
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Paramyxovirus genome organisation.  Gene maps for representative members of 
each genus of the Paramyxovirinae and Pneumovirinae subfamilies are shown. The nucleotide 
length of each viral genome (nt), the intergenic regions and the non-coding termini (not to scale) 
are shown.  Genes are colour-coded for function and the overlap between the RSV M2 and L 
genes is indicated.   
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1.2   Molecular Biology of paramyxoviruses 
 
1.2.1   Paramyxovirus genomes and their encoded proteins 
 
Paramyxovirus RNA genomes are non-segmented, single-stranded and 15-19 
kB in length.  Genomic RNA contains a 3’extracistronic region of approximately 
50 nucleotides (leader), and a 5’extracistronic region of 50-161 nucleotides 
(trailer), which are essential for transcription and replication.  Transcription 
control sequences are also found at the beginning and end of each gene, which 
are separated by intergenic regions.  While respirovirus intergenetic regions are 
precisely 3 nucleotides, they vary in length for pneumoviruses (1-56 
nucleotides).  Paramyxovirus genomes typically contain 5-10 tandemly-linked 
genes (Fig. 1.1), although coding capacity may be increased by the use of 
overlapping ORFs. 
 
Nucleocapsid proteins N, P, L and M2-1: Paramyxoviruses consist of a stable 
nucleocapsid core surrounded by a lipid bilayer envelope (Fig. 1.2), which is 
acquired as the virus buds from the host cell.  The nucleoprotein (N) binds to 
both negative (-) sense genomic and positive (+) sense antigenomic RNA to 
form the helical nucleocapsid template, which is the biologically active form of 
viral RNA (vRNA).  The crystal structure of an RSV-N protein complex revealed 
that the N protein is able to form decameric rings that bind to RNA via a basic 
surface groove (Tawar et al., 2009).  In addition, N also binds to both the 
phosphoprotein (P) and the large polymerase (L) to form the ribonucleoprotein 
complex (RNP), which represents the minimal replication unit for the 
Paramyxovirinae (Grosfeld et al., 1995; Yu et al., 1995).  The L protein is a viral 
RNA-dependent RNA polymerase (vRNAP), which is responsible for 
transcription of functional viral mRNA, including 5’capping and methylation and 
3’polyadenylation activities (Ogino et al., 2005).  The L protein is typically found 
in very low amounts in infected cells.  For example, each Sendai virus 
nucleocapsid is composed of approximately 2600 N, 300 P and 50 L proteins 
(Lamb et al., 1976).  While the L protein contains all vRNAP catalytic activities, 
L binds to the nucleocapsid template via the P protein (Horikami et al., 1992).  
The P protein is phosphorylated on Ser/Thr residues, and is an essential 
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cofactor for both the L and N proteins.  Finally, the M2-1 protein (unique to the 
pneumovirus genome), is also incorporated into the RSV nucelocapsid.  The 
M2-1 protein is transcribed from the first M2 gene ORF, and acts as an 
essential transcription factor to promote processivity of the pneumovirus 
polymerase (Collins et al., 1995).   
 
 
 
Figure 1.2.  The paramyxovirus virion.  Schematic representation of a paramyxovirus virion 
(not drawn to scale), with proteins coloured according to Fig. 1.1.  Fusion (F) and attachment 
(H, HN or G) proteins are inserted into the lipid bilayer envelope.  In addition, some 
paramyxoviruses, including RSV, also contain a small hydrophobic (SH) envelope glycoprotein 
(not shown).  Negative-strand RNA associates with the nucleoprotein (N), phosphoprotein (P), 
and large polymerase (L) proteins to form the ribonucleocapsid (RNP).  Figure provided by 
Alfonsina Trento (ISCIII, Madrid, Spain). 
 
Matrix protein M: As shown in Fig. 1.2, the matrix (M) protein forms a layer on 
the inner face of the envelope.  The M protein is thought to act as a central 
organiser of viral morphogenesis via interactions with the cytoplasmic tails of 
envelope glycoproteins, the lipid bilayer and the nucleocapsid.  The ability of the 
M protein to self associate, combined with its interaction with the nucleocapsid, 
may provide the driving force for formation of budding virions (for a review, see 
Ghildyal et al., 2006). 
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Envelope glycoproteins G/H/HN, F and SH: Paramyxoviruses contain two 
virally encoded integral membrane glycoproteins within the lipid envelope: the 
fusion (F) and attachment (glycoprotein [G], haemagglutinin [H] or 
haemagglutinin-neuraminidase [HN]) proteins, which form spikes that extend 8-
12 nm from the surface (Fig 1.2).  All paramyxoviruses possess a fusion protein 
that mediates fusion of the viral and cellular membranes during virus entry.  
However, the nature of the attachment protein, which is responsible for binding 
of the virus to target cell surface receptors, varies between distinct members of 
the Paramyxoviridae.  Paramyxovirus fusion and attachment glycoproteins 
represent important antigenic targets, since they induce neutralising and 
protective antibodies (Walsh et al., 1987).  Given the focus of this thesis on 
paramyxovirus cell entry, the fusion and attachment proteins will be discussed 
in detail in section 1.3.   
 
In addition, mumps virus, PIV5 and RSV encode a third integral membrane 
protein of unknown function: the small hydrophobic (SH) protein.  The SH 
protein is not required for RSV entry or spread in vitro (Techaarpornkul et al., 
2001), although RSV lacking the SH protein is attenuated in vivo (Bukreyev et 
al., 1997).  Indeed, paramyxovirus SH proteins have been shown to inhibit 
TNFα signaling and prevent infected cells from undergoing apoptosis, which 
may be beneficial for virus replication (Fuentes et al., 2007; Wilson et al., 2006).  
Furthermore, electron microscopy of RSV SH protein revealed pentameric and 
hexameric ring-like structures containing a central pore that could allow the 
passage of ions and small molecules (Carter et al., 2010).   
  
Accessory proteins: The paramyxovirus P/V/C gene directs the expression of 
a number of accessory proteins (V, W, C', C, Y1 and Y2 for SeV) via RNA 
editing and the use of alternative translation codons.  Although non-essential for 
infectivity, the paramyxovirus accessory proteins exert multiple functions on 
viral growth, including negative regulation of RNA synthesis and inhibition of 
cellular components of the type I interferon response (for a review see 
Goodbourn and Randall 2009).   The pneumoviruses are unique within the 
Paramxyovirinae since they do not produce alternative proteins from the P 
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gene.  However, RSV possesses two additional genes that encode non-
structural proteins NS1 and NS2, which have been shown to independently 
inhibit induction of the type I interferon response to viral infection (Spann et al., 
2004).  These non-structural proteins enhance the growth of RSV, but are not 
essential for virus replication in vivo (Teng et al., 1999; 2000).   
  
1.2.2 Replication Cycle 
The entire replication cycle of the Paramyxoviridae takes place in the cytoplasm 
of the host cell (Fig. 1.3).  Viral entry initially involves binding of virions to the 
target cell surface.  For members of the Rubulavirus and Respirovirus genera, 
sialic acid-containing molecules serve as cell surface receptors.  Sialic acid-
containing gangliosides are thought to function as the cellular receptor for the 
Sendai virus HN attachment protein (Markwell et al., 1980; 1984).  While the 
specific cell surface receptor for pneumoviruses is not known, RSV interacts 
with cell surface glycosaminoglycans, in particular with heparan sulphate 
(Escribano-Romero et al., 2004; Feldman et al., 1999; Feldman et al., 2000; 
Hallak et al., 2000; Karger et al., 2001; Krusat and Streckert 1997; Martínez and 
Melero 2000; Techaarpornkul et al., 2002).  Following attachment, the 
paramyxovirus fusion (F) protein mediates fusion of the viral envelope with the 
cellular plasma membrane at neutral pH.   
 
Fusion results in the delivery of the nucleocapsid into the cytoplasm, where 
transcription of the viral genome is carried out by the vRNAP, generating a set 
of mRNAs that are translated by cellular ribosomes.  The vRNAP transcribes 
the (-) sense genomic template in a sequential manner from a single promoter 
at the 3’ end of the vRNA to generate capped and polyadenylated mRNAs.  
Transcription initiates at the first gene start (GS) signal of the 3’-terminal gene 
and proceeds along the genome until a gene end (GE) sequence is reached.  
The vRNAP subsequently scans the intergenic region without dissociating from 
the template and reinitiates at the next downstream GS signal in a “start-stop” 
mechanism of transcription.  This results in a 3’-5’ polar gradient of mRNA 
abundance, as the likelihood of the polymerase reinitiating at a downstream GS 
signal is reduced at each gene junction.  Upon translation of the primary 
transcripts and accumulation of viral proteins, the viral genome is replicated to 
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produce a full-length, (+) sense antigenome (cRNA).  The antigenome 
represents an intermediate in genome replication, since it complexes with the N 
protein and acts as a template for the further synthesis of progeny genomes.  
Efficient replication of SeV RNA depends on the “rule of six”, which specifies 
that the viral genome must be of polyhexameric length in order to replicate 
efficiently (Calain and Roux 1993).  In contrast, replication of the RSV genome 
does not obey the rule of six (Samal and Collins 1996).  In common with other 
enveloped viruses, paramyxoviruses bud from the host cell plasma membrane 
at sites where viral components have assembled.  Emerging buds then pinch 
off, resulting in the release of progeny virus particles.         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.  The Infectious cycle of paramyxoviruses.  Schematic representation of the 
paramyxovirus replication cycle (see text for details).  The upper part of the figure illustrates 
attachment, fusion and entry of the virus, resulting in release of the (-) sense nucleocapsid into 
the cytoplasm, where transcription and replication take place.  mRNA transcripts are indicated 
by horizontal lines, with the gradient of decreasing molecular abundance of the mRNAs also 
illustrated.  The right of the figure depicts assembly of viral proteins at the plasma membrane, 
where buds emerge and pinch off, resulting in the release of virions.  Figure provided by 
Alfonsina Trento (ISCIII, Madrid, Spain). 
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1.3  Paramyxovirus envelope glycoproteins 
 
1.3.1 The paramyxovirus fusion protein 
 
Paramyxovirus fusion proteins mediate virus entry by fusion between the viral 
envelope and cellular plasma membrane at neutral pH.  In addition, F proteins 
expressed at the plasma membrane of infected cells can fuse with neighbouring 
cells to form multinucleated syncytia.  Despite low sequence identity, 
paramyxovirus F proteins share structural elements, including the location of 
cysteine, glycine and proline residues, suggesting a similar structure for all 
paramyxovirus F proteins.  As shown in Fig. 1.4A, the F protein contains three 
principal hydrophobic regions: an N-terminal signal peptide (SP) that directs 
translocation to the ER during biosynthesis, a C-terminal transmembrane 
anchor (TM), and a fusion peptide (FP), located at the N terminus of F1.  The 
fusion peptide inserts into the target cell membrane during membrane fusion 
(Russell et al., 2001).  Paramyxovirus F proteins are also characterised by two 
4-3 heptad repeat sequences, HRA and HRB, located adjacent to the fusion 
peptide and transmembrane domain, respectively, which play crucial roles in 
the mechanism of membrane fusion (see section 1.3.3). 
 
The paramyxovirus F protein is a homotrimer (Russell et al., 1994) and belongs 
to the class I family of viral fusion proteins, which includes influenza virus 
haemagglutinin (HA) protein, the HIV-1 gp160 envelope protein and the Ebola 
virus G protein.  Membrane fusion occurs via refolding of a prefusion, 
metastable form of the F protein (Fig. 1.4B) to a more stable, postfusion state 
(Fig. 1.4C) via large conformational changes (for a review see Lamb and 
Jardetzky 2007).  Such conformational changes result in the assembly of F 
protein heptad repeat regions (HRA and HRB) into a 6-helix bundle (6HB), 
which is characteristic of the postfusion structure (Fig. 1.4C).  The 6HB is a 
trimeric, coiled-coil structure, consisting of an internal core of three HRA helices 
surrounded by three anti-parallel HRB helices, (Baker et al., 1999; Zhao et al., 
2000).  This arrangement positions the fusion peptide and transmembrane 
domain at the same end of the F protein, and is thought to be directly linked to 
Introduction 
 
27 
merging of viral and cell membranes, with the free energy released on 6HB 
formation driving membrane fusion (Melikyan et al., 2000; Russell et al., 2001).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.  Schematic diagram of the respiratory syncytial virus (Long strain) and Sendai 
virus (Harris strain) fusion proteins.  (A) The fusion (F) protein is synthesised as a precursor 
(F0), which requires proteolytic cleavage at single (F_SeV) or double (F_RSV) cleavage site(s) 
to generate disulphide-linked F2-F1 polypeptides.  Paramyxovirus fusion proteins contain three 
main hydrophobic regions: the signal peptide (SP), the fusion peptide (FP) at the N terminus of 
F1, and the transmembrane region TM.  Also shown are the heptad repeat regions A and B 
(green and blue, respectively).  Three-dimensional models of the trimeric prefusion (B) and 
postfusion (C) structures of RSV F protein are shown, with cleavage sites in the prefusion form 
indicated by arrows.  The backbone is shown in grey and a single monomer is coloured 
according to the same scheme as in part (A).  Models were built using the SWISS-MODEL 
server facilities (http://swissmodel.expasy.org/) and the atomic coordinates of the prefusion 
structure of the parainfluenza virus 5 F protein (Protein Data Bank code 2B9B) or the postfusion 
structure of the parainfluenza virus 3 F protein (Protein Data Bank code 1ZTM) as templates 
(Yin et al., 2005; 2006).  Figures 1.4B and 1.4C were provided by Margarita Magro (ISCIII, 
Madrid, Spain).  
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The F polypeptide is synthesised as an inactive precursor (F0), which requires 
proteolytic cleavage to yield fusion-competent, disulphide-linked F2-F1 
polypeptides (reviewed in Lamb et al., 2006; Lamb and Jardetzky 2007).  
Cleavage takes place at either a mono- or multi-basic cleavage site, recognised 
by trypsin- or furin-like proteases, respectively, immediately upstream of the 
hydrophobic fusion peptide.  Cleavage is an absolute requirement in order to 
prime the F protein for membrane fusion.  Furthermore, the nature of the 
cleavage motif has been shown to act as a key determinant of viral 
pathogenicity, since the acquisition of a multibasic cleavage motif is linked to 
increased pathogenicity and systemic infection (Klenk and Garten 1994; Nagai 
and Klenk 1977).   
 
A comparison of the sequences of representative paramyxovirus F protein 
cleavage sites is given in Table 1.1.  The intracellular subtilisin-like protease 
furin is thought to cleave paramyxovirus proteins with multibasic cleavage sites, 
including the RSV F protein (F_RSV).  In contrast, Sendai virus F protein 
(F_SeV) possess a single basic amino acid at the cleavage site (R116), and 
requires the addition of trypsin to cell cultures in order to undergo multiple 
rounds of replication (Scheid and Choppin 1974; Kido et al., 1999). It is thought 
that the trypsin-like serine protease tryptase Clara, which is secreted from Clara 
cells of the bronchial epithelium, is responsible for activating paramyxoviruses 
with monobasic cleavage sites in the murine host respiratory tract (Kido et al., 
1997; 1999).  
 
F_RSV is unique among the paramyxoviruses, since F_RSV possesses two 
(rather than one) furin cleavage sites (site I, RARR109 and site II, 
KKRKRR136), which are separated by a region of 27 amino acids (pep27).  The 
two cleavage sites and the length, but not the sequence, of pep27 are highly 
conserved in all bovine and human RSV strains.  Proteolytic processing at both 
cleavage sites is required by F_RSV to fuse transfected cells to form syncytia 
(González-Reyes et al., 2001; Zimmer et al., 2001a).  Interestingly, while 
membrane fusion by F_RSV does not depend on co-expression of an 
attachment protein (see section 1.3.4), there is a requirement for double 
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cleavage of the F protein and removal of the intervening pep27, which is 
secreted into the cell culture medium (Ruiz-Argüello et al., 2002).  While the 
presence of two cleavage sites in F_RSV is unique among paramyxoviruses, 
two cleavage sites have also been observed in the severe acute respiratory 
syndrome (SARS) coronavirus spike (S) protein (Belouzard et al., 2009). 
  
Table 1.1.  Paramyxovirus fusion protein cleavage site sequences. 
Virus1 
Cleavage Site 
Sequence2  
SeV GVPQSR116  
HPIV1 DNPQSR 
HPIV3 DPRTKR 
PIV5 TRRRRR 
Mumps SRRHKR 
NDV (avirulent) GGRQGR 
NDV (virulent) GRRQKR    
Measles SRRHKR 
RSV RARR109  KKRKRR136 
 
1HPIV, human parainfluenza virus; PIV5, parainfluenza virus 5; NDV, Newcastle disease virus. 
2Basic residues are indicated in boldface.  Cleavage takes place at the C-terminal arginine 
residue (indicated by an arrow for SeV).  Adapted from Harcourt et al., 2000. 
 
The function of double cleavage and subsequent pep27 removal are currently 
unknown, although completion of cleavage is associated with a change in 
shape of RSV F protein (Melero 2007; Ruiz-Argüello et al., 2002).  An 
immunomodulatory role has been suggested for bovine RSV (BRSV) pep27 
(Zimmer et al., 2003), however no such role has been attributed to the human 
RSV intervening peptide, which does not share sequence similarity with its 
bovine counterpart.     
 
The crystal structures of the pre- and post-fusion forms of three paramyxovirus 
F proteins have recently been solved, revealing substantial conformational 
differences between the two structures (Swanson et al., 2010; Yin et al., 2005; 
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2006).  Three-dimensional models of the pre- and post-fusion forms of the RSV 
F protein were constructed based on the published structures for the prefusion 
PIV5 (Fig. 1.4B) and postfusion HPIV3 proteins (Fig. 1.4C).   The overall shape 
of the prefusion form is that of a globular head attached to a rod-like stalk, 
which is formed by the triple stranded, coiled-coil adopted by HRB.  The top of 
the globular head is formed by HRA and the fusion peptide, which is mostly 
buried between subunits of the globular head.  The positioning of the fusion 
peptide resembles that of the prefusion structure of influenza virus HA (Skehel 
and Wiley 2000).  Although its conformation is unknown, the glycosylated, 
intervening region between the two RSV cleavage sites (pep27) is predicted to 
form a solvent-accessible loop.  As shown in Fig. 1.4C, the postfusion form can 
be related to the prefusion form by flipping the stalk domain relative to the head.  
During the fusion process (see section 1.3.3), the HRA region refolds to form a 
single, extended alpha-helical conformation and interacts with HRB to form the 
postfusion 6HB. 
 
1.3.2 Paramyxovirus attachment proteins 
 
Paramyxovirus attachment proteins (G, H or HN, depending on the virus) differ 
widely in their structure and receptor usage.  Sendai virus, in common with 
other members of the Respirovirus and Rubulavirus genera, possesses an 
attachment protein with haemagglutinin-neuraminidase (HN) activity.  Binding of 
HN to sialic acid-containing receptors on the cell membrane is thought to 
mediate attachment of the virus to the target cell, whereas HN neuraminidase 
activity may prevent self-aggregation of budding virus particles and facilitate 
virus spread (for a review, see Villar and Barroso 2006).  The HN protein also 
promotes fusion, and co-expression of homotypic F and HN proteins is required 
for fusion of most paramyxoviruses (Horvath et al., 1992).  It has been proposed 
that receptor binding of the HN protein induces conformational changes that 
activate or trigger the F protein for fusion (Russell et al., 2001). 
 
The HN protein (Fig. 1.5) is a class II integral membrane protein, which is 
characterised by an N terminal-proximal transmembrane anchor region that acts 
as a signal peptide for translocation to the ER during biosynthesis, a 
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membrane-proximal stalk domain and a large C-terminal globular head domain 
that contains receptor-binding and neuraminidase activities (Thompson and 
Portner 1987).  The structure of the HN globular head domain (Fig. 1.5B) 
exhibits the six-blade propeller fold typical of other neuraminidase structures 
(Crennell et al., 2000; Lawrence et al., 2004; Yuan et al., 2005).  Although it 
was initially thought that both receptor-binding and neuraminidase activities 
were located at the same site, studies on both Newcastle disease virus (NDV) 
and SeV HN proteins suggest the presence of a second sialic acid binding site 
at the dimer interface (Bousse et al., 2004; Bousse and Takimoto 2006; Zaitsev 
et al., 2004).  For NDV, it has been postulated that engagement of the first site 
activates the second site, thus ensuring that the virus remains in close proximity 
to the target cell membrane during infection (Porotto et al., 2006).   
 
The HN protein forms homotetramers via the stalk region (Yuan et al., 2005), 
which may also interact with the F protein in order to promote fusion (see 
section 1.3.4).  Indeed, studies using mutant HN proteins have demonstrated 
that the F protein-triggering function of HN that activates the F protein for 
membrane fusion resides in the HN stalk domain (Porotto et al., 2003).  The fine 
balance between receptor-binding, receptor cleavage and F-triggering 
properties of HN is thought to regulate viral entry.   
 
The structure of the pneumovirus attachment (G) protein (Fig. 1.5) differs widely 
from the paramyxovirus HN attachment protein, since G lacks either 
haemagglutinating or neuraminidase activitvities, and does not bind to sialic 
acid.  The RSV G protein is a type II integral membrane protein with a single N-
terminal hydrophobic signal/transmembrane anchor domain.  RSV G protein is 
characterised by two heavily glycosylated mucin-like domains, and migrates on 
SDS-PAGE with a higher molecular weight than predicted due to extensive O-
glycosylation.  In contrast to the requirement for the paramyxovirus HN protein 
in fusion promotion, the pneumovirus G protein is not essential for cell-cell or 
virus-cell fusion (Biacchesi et al., 2004; Karron et al., 1997; Schmidt et al., 
2002; Schowalter et al., 2006; Techaarpornkul et al., 2001; Techaarpornkul et 
al., 2002).   
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Figure 1.5. Comparison of the Sendai virus HN and respiratory syncytial virus G 
attachment proteins.  (A) The primary structures of SeV HN (Harris strain) and RSV G (Long 
strain) attachment proteins are shown.  Cytoplasmic tail regions (CT) and transmembrane (TM) 
regions are shown in blue and black, respectively.  The HN stalk region, which has been 
proposed to interact with the prefusion F protein, is shown in green.  Highly O-glycosylated, 
mucin-like domains of RSV G protein are indicated by arrows and cysteine residues overlapping 
the central conserved domain are represented by solid circles.  (B) Crystal structure of the 
tetrameric NDV HN globular head region (Zaitsev et al., 2005; Protein Data Bank code 1USR).  
The two sialic acid binding sites, indicated by arrows, are occupied by Neu5Ac2en (2-deoxy-
2,3-dehydro-N-acetylneuraminic acid), shown in green at the active site (site I), or by the 
thiosialoside Neu5Ac-2-S-α(2,6)Gal1OMe at site II (yellow). (C) Schematic model of the 3-
dimensional structure of the transmembrane G protein (Gm).  While Gm is tetrameric, a dimer is 
shown for simplicity.  The CT and TM regions, cystine noose and the proposed heparin binding 
domain (HBD) are indicated.  Fig. 1.5C provided by Alfonsina Trento (ISCIII, Madrid, Spain). 
 
As shown by the model in Figure 1.5C, the RSV G mucin-like regions are 
predicted to form extended, unfolded domains, which are separated by a central 
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conserved region that is devoid of glycosylation sites. This region contains four 
conserved cysteine residues, which form two disulphide bridges, resulting in a 
cystine noose.  While the central conserved region is not required for efficient 
replication of RSV, it may play an immunomodulatory role (Polack et al., 2005).  
A short segment adjacent to the cystine noose has been identified as a heparin 
binding domain (HBD), which mediates binding of the G protein to cell surface 
glycosaminoglycans (GAGs), (Feldman et al., 1999).   
 
The G protein is produced as both (i) a type II transmembrane protein (Gm) that 
is incorporated into the virion envelope via a hydrophobic region near the N-
terminus and (ii) by alternative translation initiation as a soluble protein (Gs), 
which lacks the membrane anchor region and is secreted from infected cells 
(Hendricks et al., 1987).  While Gm forms homo-oligomers (probably tetramers), 
Gs remains monomeric, suggesting that the transmembrane region is required 
for oligomerisation (Escribano-Romero et al., 2004).  While Gm is responsible 
for attachment to target cell GAGs during viral entry, it has been postulated that 
Gs may act as an antibody decoy or play an immunomodulatory role.   
 
1.3.3  Model of paramyxovirus fusion                                            
 
Earlier studies performed using peptides representing the heptad repeat regions 
revealed that both HRA and HRB are exposed by conformational changes of 
the F protein during fusion, before they refold to the final, thermostable 6 helix 
bundle (6HB) structure (Russell et al., 2001).  Subsequent elucidation of crystal 
structures of the pre- and post fusion forms of the F protein gave rise to a 
hypothesised mechanism of membrane fusion, summarised in Fig. 1.6 (Yin et 
al., 2006).  In the first step, the HRB helices melt and separate from the 
prefusion head region (Fig. 1.6B).  This “open stalk” intermediate refolds to form 
a “prehairpin” intermediate, in which the HRA coiled-coil assembles, resulting in 
translocation of the fusion peptide towards the target cell membrane (Fig. 1.6C).  
Final refolding of the HRB region to form the 6HB results in formation of a fusion 
pore, which leads to membrane fusion (Fig. 1.6D).  In the final, postfusion form 
of the F protein, both the transmembrane anchor and fusion peptide are present 
in the same membrane (Fig. 1.6E).         
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Figure 1.6.  Model of paramyxovirus fusion. 
(A) Structure of the prefusion conformation of the F protein.  Residues corresponding to the 
HRA and HRB helices are coloured green and blue, respectively. (B) Open stalk conformation, 
in which the HRB stalk melts and separates from the prefusion head region.  (C) Prehairpin 
intermediate, in which the HRA coiled-coil has formed, permitting insertion of the fusion peptide 
into the target cell membrane.  (D)  Close approach of the cellular and viral membranes via 
refolding of the HRB linker region.  (E) Formation of the postfusion form of the F protein, 
characterised by a 6-helix bundle (6HB) and juxtaposition of the fusion peptide and 
transmembrane regions, which is linked to pore formation and membrane fusion.  Figure 
reproduced from Yin et al 2006. 
 
1.3.4  Role of the attachment protein in paramyxovirus fusion                                            
 
It has been hypothesised that the HN protein lowers the activation energy 
required for F-mediated membrane fusion (Paterson et al., 2000) and triggers F-
mediated membrane fusion “at the right time and in the right place” following 
binding to target cell sialic acid receptors (Lamb et al., 1993).  An interaction 
between the F and HN proteins has been demonstrated on the surface of 
A B C
D E
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transfected (Deng et al., 1999) or infected cells (Stone-Huslander and Morrison 
1997).  Studies conducted with chimeric HN proteins have suggested that the 
HN stalk and globular head regions (Deng et al., 1995; Tanabayashi and 
Compans 1996; Tsurudome et al., 1995) are involved in interactions with the F 
protein.  Two models have been proposed to account for how HN may trigger F 
protein activation (Connolly et al., 2009).  In the first model (termed the clamp 
model), HN interacts with the F protein before binding to target cells in order to 
stabilise the F protein in a metastable state.  Conformational changes that take 
place in the HN protein as a result of attachment to target cell sialic acid act to 
release the F protein for fusion.  An alternative model (the provocateur model), 
hypothesises that conformational changes in HN following receptor binding 
actively trigger fusion by destabilising the F protein.  According to this second 
model, an interaction between HN and F could take place either before or after 
receptor binding.  However, the nature of the conformational changes in HN and 
their precise effect on the F protein remain to be determined.     
 
While Sendai virus F protein, in common with most other members of the 
Paramyxoviridae subfamily, requires co-expression of the HN attachment 
protein in order to fuse cells in culture, RSV F protein is able to fuse 
membranes in the absence of the attachment G protein.  Spontaneous mutants 
or genetically engineered recombinant RSV expressing F as the only surface 
glycoprotein are able to infect cells and form syncytia (Karron et al., 1997; 
Schmidt et al., 2002; Techaarpornkul et al., 2001; Techaarpornkul et al., 2002).  
Furthermore, expression of the RSV F protein as the only viral protein in 
transfected cells is sufficient to induce syncytia formation (González-Reyes et 
al., 2001; Zimmer et al., 2001a).  F_RSV binds to heparan sulphate-like 
glycosaminoglycans (GAGs), (Feldman et al., 2000; Techaarpornkul et al., 
2002), which may mediate attachment in the absence of the G protein.  The 
human metapneumovirus (HMPV) F protein also induces syncytia formation in 
transfected cells in the absence of the G protein, which is dependent on low pH 
for some strains (Herfst et al., 2009; Schowalter et al., 2006; 2009).  Thus, the 
precise role in fusion of attachment proteins belonging to members of the 
Pneumovirinae subfamily is not known, and it appears that pneumovirus F 
proteins possess alternative mechanisms for attachment and fusion.   
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2.  AIMS 
 
RSV is unique among the paramyxoviruses, since (a) RSV is able to fuse and 
infect cells in the absence of a separate attachment protein, and (b) the RSV F 
protein contains double furin cleavage sites, separated by a conserved 
intervening region (pep27).  Thus, we aimed to investigate the relevance of the 
F_RSV double cleavage sites for fusion and infection in the context of the SeV 
F protein, which (a) requires co-expression of the HN attachment protein for 
fusion and infection, and (b) possesses a single trypsin-dependent cleavage 
site.  We proposed the following aims: 
 
1. Subclone SeV F and HN proteins in the pTM1 plasmid and confirm their 
expression in transfected BSR-T7/5 cells. 
2. Construct a series of chimeric F_SeV mutants by insertion of one or both 
F_RSV cleavage sites in F_SeV, separated either by a partial or 
complete intervening pep27 sequence. 
3. Compare the expression and proteolytic processing of cleavage site 
mutant F_SeV proteins in transfected cells. 
4. Evaluate the ability of cleavage site F_SeV mutants to fuse transfected 
cells in the absence or presence of (a) trypsin and/or (b) the HN protein. 
5. Subclone F_SeV cleavage mutants in the FL5 plasmid (SeV cDNA),  and 
rescue recombinant SeV (rSeV) by co-transfection of BSR-T7/5 cells with 
FL5 and support plasmids.  
6. Compare the replication rate of the distinct rSeV over multiple cycles of 
infection. 
7. Assess the thermostability of rSeV by haemolysis and titration assays.  
8. Evaluate the relative abilities of rSeV to fuse infected cells (a) in the 
absence or presence of trypsin and (b) at distinct temperatures. 
9. Analyse the dependency of rSeV on the interaction with sialic acid 
receptors for cell-cell fusion and infection. 
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3.  MATERIALS AND METHODS 
 
3.1. BIOLOGICAL MATERIALS 
 
3.1.1   Cell lines 
 
BHK-21  
Syrian golden hamster (Mesocricetus auratus) kidney cells.  American type 
culture collection (ATCC): CCL-10. 
 
BSR-T7/5  
BHK-21-derived cell line that constitutively expresses the T7 bacteriophage 
RNA polymerase (Buchholz et al., 1999).   
 
LLC-MK2 
Rhesus monkey (Macaca mulatta) kidney cells. ATCC: CCL-7. 
 
Pro-5 
Chinese hamster ovary (Cricetulus griseus; CHO) cells that represent the 
parental line for the Lec2 glycosylation mutants.  Pro-5 cells are proline 
auxotrophs and are thus grown in Alpha Minimum Essential Medium (AMEM), 
which contains 40mg/L proline.  ATCC: CRL-1781. 
 
Lec2 
Sialic acid-deficient cells derived from the Pro-5 cell line by selection for 
resistance to wheat germ agglutinin.  ATCC: CRL-1736, (Stanley et al., 1975). 
 
3.1.2 Virus 
Recombinant Sendai Virus (rSeV) from the Z strain was rescued from full 
length cDNA (FL5 plasmid), which was kindly provided by D. Kolakofsky, 
Geneva, Switzerland (see sections 3.1.4 and 3.3.2.4). 
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3.1.3 Animals 
Eight-month-old BALB/c mice were used for the production of ascitic fluid 
expressing the GB5 monoclonal antibody directed against the SeV F protein 
(see sections 3.1.5 and 3.3.1).   
 
New Zealand rabbits were employed in the production of a polyclonal serum 
recognising the N-terminal 25 amino acids of the SeV HN protein cytoplasmic 
tail (CT) region (see sections 3.1.5 and 3.3.1). 
 
Eight-to-ten-day-old embryonated chicken eggs (La Granja, Madrid) were 
employed in the rescue and amplification of recombinant SeV (see section 
3.3.2.4). 
 
Dunkin-Hartley guinea pigs were bled at two-week intervals for haemolysis 
experiments (see section 3.3.5.3) and stored at 4ºC in Alsever’s solution (one 
part blood to one part Alsever’s). 
 
3.1.4 Bacteria and Plasmids 
Escherichia coli DH5α strain (Hanahan et al., 1983) or XL1-Blue competent 
bacteria (Stratagene) were cultivated in the following media supplemented with 
100 µg/ml ampicillin: 
 
LB medium (MP Biomedicals: 1% tryptone, 1% NaCl and 0.5% yeast extract). 
 
NZY+ (1% casein hydrolysate, 0.5% yeast extract [Becton Dickinson], 0.5% 
NaCl, 12.5 mM MgCl2, 12.5 mM MgSO4, 20 mM glucose). 
 
Circle-Grow® solid media (Qbiogene).  
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The following plasmids were employed in cloning and mutagenesis (see section 
3.3.3): 
 
pGEM4 
2871 bp plasmid carrying T7 and SP6 promoters.  The genes encoding Sendai 
virus F and HN proteins were originally provided in the pGEM4 plasmid by L. 
Roux, Geneva, Switzerland. 
 
pTM1 
5357 bp plasmid containing the T7 promoter and the encephalomyocarditis 
virus (ECMV) UTR, which increases the efficiency of translation (Moss et al., 
1990).  SeV F and HN genes were subcloned from the pGEM4 plasmid into 
pTM1, and subsequently subjected to mutagenesis (section 3.3.3). 
 
FL5 
18294 bp plasmid (a gift from D. Kolakofsky, Geneva, Switzerland), which 
contains the complete SeV cDNA (Z strain) and a number of unique restriction 
sites.  Mutant SeV F genes (Harris strain) were cloned into the FL5 plasmid, 
and recombinant SeV was rescued as detailed in section 3.3.2.4. 
 
3.1.5 Antibodies 
 
GB5 
Monoclonal antibody (MAb) that recognises the SeV F protein F1 polypeptide.  
GB5 was obtained from the ascitic fluid of BALB/c mice injected with GB5 
hybridoma cells (a gift from S. Wharton and J.J Skehel, London, UK). See 
section 3.3.1. 
 
2F 
MAb that recognises the RSV F protein (García-Barreno et al., 1989). 
 
F_SeV_CT 
Polyclonal serum recognising the cytoplasmic tail (CT) of F_SeV (a gift from L. 
Roux, Geneva, Switzerland).   
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HN_SeV_CT 
Polyclonal serum that recognises the CT of HN_SeV was prepared by 
inoculation of New Zealand rabbits with a peptide corresponding to the N-
terminal 25 amino acids of the HN CT (see section 3.3.1).   
 
F_RSV_104-117 
Polyclonal serum that recognises a peptide corresponding to amino acids 104-
117 of the RSV F protein (González-Reyes et al., 2001). 
 
3.1.6 Oligonucleotides 
 
Table 3.1 Oligonucleotides employed in this study 
Oligonucleotidea Use Sequence 
F_NcoI+ Cloning of SeV F in pTM1 
GCACATGCCATGGACAGCATATATCC
AGAGGTCAC 
F_SpeI- Cloning of SeV F in pTM1 
GCTCAGGACTAGTTCATCGTTTCTCAG
CCATCGCA 
HN_NcoI+ Cloning of SeV HN in pTM1 
GCACATGCCATGGATGGTGATAGGGG
CAAACG 
HN_SpeI- Cloning of SeV HN in pTM1 
GCTCAGGACTAGTTTAAGACTCGGCC
TTGCATA 
G_NcoI+ Cloning of RSV G in pTM1 
GCACATGCCATGGTCCAAAAACAAGG
ACCAACGCACCGC 
G_SpeI- Cloning of RSV G in pTM1 
GCTCAGGACTAGTCTACTGGCGTGTT
GTGTTGGGTGG 
F_MluI+ Cloning of SeV F in FL5 
AACTTAGGGATAAAGTCCCTTGTGAAC
GCGTGGTTGCAAAACTCTCCCCTTGG
GAAACATGACAGCATATATCCAGAGG
TCACAGTGC 
F_RsrII- Cloning of SeV F in FL5 
TAAGTTTTTCTTATTATATACAGATCGG
ACCGAATACCATGCCTGCTTTACAAGA
CATCTGATAATGGTCGTGAAGTTCATC
GTTTCTCAGCCATCGCATCAAACC 
F_RKR+ Cleavage site
b
 
mutation of SeV F 
GCCGGTGTTCCACAGTCGAAGAAAAG
GAAAAGAAGATTCTTCGGTGCTG 
F_KKRKR+ Cleavage site 
mutation of SeV F 
GCCGGTGTTCCACAGTCGAAGAAAAG
GAAAAGAAGATTCTTCGGTGCTG 
F_110+ Cleavage site 
mutation of SeV F 
GATCTTCAGGAGGCTCTGATAACTGC
AAACAATCGAGCCAGAAGAGAAGTCA
CCAATGATACGACACAAAATGCC 
F_117+ Cleavage site 
mutation of SeV F 
CTGCAAACAATCGAGCCAGAAGAGAA
CTACCAAGGTTTATGAATTACACCAAT
GATACGACACAAAATGCCGGTG 
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F_∆+ Cleavage site mutation of SeV F 
GCCAGAAGAGAACTACCAAGGTTTAT
GAATTACACCTCGAAGAAAAGGAAAA
GAAGATTCTTCGGTGC 
F_130+ Cleavage site 
mutation of SeV F 
GCCAGAAGAGAACTACCAAGGTTTAT
GAATTACACCCTCAACAATACCAAAAA
AACCAATGTAACATTATCGAAGAAAAG
GAAAAGAAGATTCTTCGGTGC 
F_231- Sequencing of SeV F CAGCCTGTTCAGTAGGCTCTTGTAC 
F_590- Sequencing of SeV F 
CAGTCTTAAGGCAGCAGTCTCACAGC
CT 
F_663+ Sequencing of SeV F CGGCTCGAATTTCGGAACCATCGGA 
F_1009+ Sequencing of SeV F GATTGTGTTGAGTCCAGATTGACCT 
F_1460+ Sequencing of SeV F CCTCTCTGAGGTAGGTAGATGGT 
FL5+ Sequencing of Sev F (in FL5) 
GTGCACCCATCAGAGACCTGCGACAA
TGC 
HN_274- Sequencing of SeV HN CTTGCGATAACCTCTTGCCT 
HN_642+ Sequencing of SeV HN AGGTTGTGCTGACATAGGGA 
HN_721- Sequencing of SeV HN TGGGACACTACGGGGTTAAG 
HN_1089+ Sequencing of SeV HN CACATGCAATGAGGCTCTG 
HN_1509+ Sequencing of SeV HN CAACCCAACAATCATGTATT 
OG_551+ Sequencing of RSV G ATCCAACCTGCTGGGCTATCT 
OG_788+ Sequencing of RSV G TCACAAGTCAAATGGAAA 
aThe positive (+) sign indicates oligonucelotides with the same polarity as the target cDNA, 
whereas the negative (-) sign indicates oligonucelotides of opposite polarity.  bFor 
oligonucleotides employed in cleavage site mutation, the complementary (-) oligonucleotide is 
not shown. 
 
3.1.7  Enzymes 
The QuikChange® Site Directed Mutagenesis kit (Stratagene) was used in 
order to generate the F_SeV mutants detailed in Fig. 4.3. 
 
Automated DNA sequencing kit Big Dye 3.1 (Abi Prism, Biosystems) was 
employed in the sequencing of viral genes. 
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Restriction enzymes used in cloning (Nco I, Spe I, Mlu I and Rsr II) were 
obtained from Roche. 
 
Other enzymes employed in the manipulation of nucleic acids are as follows: 
shrimp alkaline phosphatase (USB, GE Healthcare), T4 DNA ligase (Rapid 
Ligation Kit, Roche), TaqPlus LongTM DNA polymerase (Stratagene), Phusion® 
High Fidelity DNA polymerase (Finnzymes) and the OneStep RT-PCR kit 
(Qiagen). 
 
Trypsin and neuraminidase (from Clostridium perfringens) were purchased from 
Sigma. 
 
3.1.8  Eukaryotic Cell Culture media 
 
Dulbecco’s Modified Eagle Medium (DMEM; Dulbecco and Freeman 1959, 
Gibco), used for the cultivation of BSR-T7/5 and LLC-MK2 cells, was 
supplemented with 4 mM glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin 
and enriched with 2.5% (DMEM-2.5%) or 10% (DMEM-10%) foetal heat-
inactivated calf serum (FCS). 
 
Alpha Minimum Essential Medium (AMEM, Sigma), used for the cultivation of 
Pro-5 and Lec2 cells, was supplemented with 4 mM glutamine, 100 U/ml 
penicillin, 0.1 mg/ml streptomycin and enriched with 2.5% FCS (AMEM-2.5%) or 
10% FCS (AMEM-10%). 
 
OPTIMEM reduced-serum medium used in transfection experiments was 
obtained from Gibco, Invitrogen. 
 
Trypsin-Versene (0.05% trypsin, 0.02% EDTA in PBS). 
 
Alsever’s solution (20.5g Dextrose, 8g Sodium citrate, 0.55g Citric acid, 4.2g 
NaCl, dissolved in 1 litre of water) is an isotonic, anticoagulant blood 
preservative, which was used for the storage of guinea pig blood. 
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3.2 REAGENTS 
 
All organic reagents (methanol, ethanol, acetone etc) were obtained from VWR. 
 
The Wizard® Plus SV Minipreps DNA Purification System (Promega) and the 
SNAP Midiprep kit (Invitrogen) were used to prepare plasmid DNA.  RNA 
extraction from cell culture supernatant was carried out using the QIAmp Viral 
RNA Mini Kit (Qiagen). 
 
Electrophoresis reagents: acrylamide, sodium dodecyl sulphate (SDS), ß-
mercaptoethanol, N-N-N’-N’-tetramethyl ethylenediamine (TEMED), 
bromophenol blue, the Precision Plus Protein Standards Dual Color molecular 
marker, Tris/Glycine/SDS (25 mM Tris, 89 mM boric acid, 2 mM EDTA, pH 8.4) 
and Tween-20 were obtained from Bio-Rad.  Agarose (Conda laboratories, 
Pronadisa) and the Benchtop 1 kb DNA ladder (Promega) were employed in 
nucleic acid separation. 
 
For Western blotting experiments, Immobilon-P (Millipore) and the Amersham 
ECL Advance Western Blotting Detection Kit (GE Healthcare) were employed in 
immunotransfer and detection of immobilised antigens, respectively.   
 
Anti-mouse/rabbit antibodies conjugated to fluorescein isothiocyanate (FITC) or 
peroxidase, biotinylated anti-mouse Ig and horseradish peroxidase-conjugated 
streptavidin were all purchased from GE Healthcare.  Streptavidin-R-
phycoerythrin (streptavidin-RPE) was purchased from Southern Biotechnology 
Associates Inc.  CNBr-activated Sepharose 4B and protein A-Sepharose CL4B 
were obtained from Pharmacia. 
 
Dimethylsulphoxide (DMSO), ampicillin, G418 antibiotic, pristane (2,6,10,14-
tetramethylpentadecane), HT (hypoxanthine-thymidine), biotin and AEC (3-
amino-9-ethylcarbazole) were obtained from Sigma. 
 
Extraction of cellular membrane proteins was carried out using the 
ProteoExtract® Native Membrane Protein Extraction Kit (Calbiochem, Bionova).   
Materials and Methods 
 
50 
For inoculation of New Zealand rabbits, Freund’s Complete Adjuvant and 
Freund’s Incomplete Adjuvant were obtained from Difco. 
 
Eukaryotic cells were transfected using the FuGENE® HD Transfection 
Reagent (Roche).  Cellular luciferase activity was detected using the Luciferase 
Assay System from Promega. 
 
Concentration of cell culture supernatant was achieved using 100 000 MW 
Vivaspin 2 ml spin columns (Vivascience, Sartorius). 
 
3.3  METHODS 
 
3.3.1 Antibody production 
 
HN_SeV_CT 
Polyclonal HN serum was obtained by intramuscular (i.m.) injection of New 
Zealand rabbits with 1 mg of a peptide (corresponding to the N-terminal 25 
amino acids of the SeV HN cytoplasmic tail region), in Freund’s complete 
adjuvant.  Inoculation was repeated a further two times in Freund’s incomplete 
adjuvant at one-month intervals.  Following the final inoculation, rabbits were 
bled a total of four times at three-week intervals.  
 
GB5 
Ascitic fluid was obtained by intraperitoneal injection (i.p.) of 0.5 ml Pristane in 
eight-month-old BALB/c mice, followed by i.p injection of 5x106 GB5 hybridoma 
cells in 0.2 ml PBS eight days later.  When tumour growth was observed (one 
week following injection), ascitic fluid was drained and clarified by 
centrifugation. 
 
GB5 MAb was purified from ascitic fluid by immunoaffinity chromatography on a 
protein A-Sepharose CL4B column (Pharmacia), and eluted in buffer containing 
1.5 M glycine, 3 M NaCl pH 8.9. 
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Purified GB5 (1 mg) was subsequently dialised overnight at 4ºC (0.1 M Na2CO3, 
0.15 M NaCl pH9) and biotinylated for use in Western blotting (see section 
3.3.4.3).  Biotin (Sigma) was dissolved in DMSO (1 mg/ml), and 100 µl were 
incubated with dialysed GB5 for 2 h at room temperature (RT) with shaking.  
Biotinylated GB5 was subsequently dialysed against PBS and optical density at 
280 nm measured to determine antibody concentration.  
 
3.3.2 Cultivation of cells and viruses 
 
3.3.2.1  Cultivation of bacteria  
XL1-Blue competent bacteria (Stratagene) and Escherichia coli DH5α bacteria 
were employed as vectors for the production of plasmid DNA.  Escherichia coli 
DH5α were prepared according to the method of Hanahan et al., (1983), and 
transformed by thermal heat shock (15 min on ice, 1 min at 42ºC, 2 min on ice).  
Transformation of XL1-Blue competent bacteria (Stratagene) was carried out by 
incubation for 30 min on ice, 45 sec at 42ºC and 2 min on ice.  Bacteria were 
subsequently incubated for 1 h at 37ºC with shaking in NZY+ medium (XL1-
Blue) or LB medium (DH5α) and plated on Circle-Grow® solid medium plates, 
supplemented with 100 µg/ml ampicillin.  Circle-Grow® plates were incubated 
for 16 h at 37ºC to allow the growth of bacterial colonies.  Individual colonies 
were selected and grown in LB medium supplemented with 100 µg/ml ampicillin 
for 16 h at 37ºC.  DNA was purified from bacterial cultivates using the Wizard® 
Plus SV Minipreps DNA Purification System (Promega) or the SNAP Midiprep 
kit (Invitrogen). 
 
3.3.2.2  Cultivation of eukaryotic cells 
Eukaryotic cells were maintained in 100 mm dishes in DMEM-10% and 
incubated at 37ºC in an atmosphere of 5% CO2 and 98% humidity.  In order to 
passage eukaryotic cells, trypsin-versane was employed to lift the cell 
monolayer.  The antibiotic G418 was supplemented to the medium of BSR T7/5 
cells on alternate passages in order to select for cells expressing T7 
polymerase.  Hybridoma cells were maintained in RPMI medium supplemented 
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with 15% FCS and hypoxanthine-thymidine (HT).  Cells were stored in liquid 
nitrogen in FCS supplemented with 10% DMSO.  
 
3.3.2.3  Transfection of eukaryotic cells 
Cells were grown to 90-100% confluence and transfected in DMEM-2.5% using                                                                          
FuGENE® HD (Roche).  Transfection mixtures were prepared in OPTIMEM 
reduced-serum medium using a ratio of 4:2 (µl FuGENE® HD:µg DNA), 
according to the manufacturer’s instructions.  The transfection mixture was 
incubated for 30 min at room temperature before being added dropwise to cells.  
Seven hours post-transfection, the transfection mixture was removed and cells 
were incubated in serum-free medium with or without 0.25 µg/ml trypsin 
(Sigma).   Extracts of transfected cells were prepared as described in section 
3.3.2.7. 
 
3.3.2.4  Rescue of Sendai virus  
BSR-T7/5 cells growing in 35 mm dishes were co-transfected with 3.5 µg full-
length Sendai virus cDNA (FL5), 1 µg pTM1-N, 1 µg pTM1-P and 0.35 µg 
pTM1-L using FuGENE® HD (see section 3.3.2.3).  Twenty four hours post-
transfection, cells were washed with serum-free DMEM and 0.5 µg/ml trypsin 
was added to the culture medium.  Cells were incubated for a further 24 h at 
33°C to allow virus growth, and fresh trypsin added at 48 h post-transfection.  
Cells were collected at 72 h post transfection in the culture medium and injected 
into nine-day-old embryonated chicken eggs, which permit the growth of SeV to 
high titres (Garcin et al., 1995).  Following incubation for 48 h at 34ºC, allantoic 
fluid was collected and clarified by low speed centrifugation.  In order to confirm 
virus rescue, allantoic fluid was pelleted through a 25% glycerol cushion for 30 
min at 15,000 rpm and loaded onto a 10% SDS-PAGE gel to detect viral 
proteins.  Alternatively, clarified allantoic fluid was purified through a 4 ml 20% 
sucrose cushion in Beckman SW28 tubes by centrifugation for 2 h at 26,000 
rpm, as previously described (Loney et al., 2009).   
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3.3.2.5  Cultivation of Sendai virus  
LLC-MK2 cells were grown to 90-100% confluence and infected with purified 
Sendai virus in a small volume of DMEM-2.5% medium (just enough to cover 
the monolayer).  Cells were incubated at 33°C or 37° C for two hours to allow 
virus absorption, before being washed in serum-free DMEM.  Cells were 
incubated in serum-free medium with or without 0.3 µg/ml trypsin until 
cytopathic effect was observed.  In order to follow the replication of SeV over 
multiple replication cycles (multi-step growth curve), LLC-MK2 cells were 
infected at an MOI of 0.05.  Over a period of 96 h, 500 µl aliquots of cell culture 
supernatant were taken at 24 h intervals, and replaced with fresh medium with 
or without 0.3 µg/ml trypsin.  The supernatant from infected cells was 
subsequently titrated as described in section 3.2.2.6. 
 
3.3.2.6  Titration of Sendai virus 
SeV was titrated by immunohistochemical staining, according to the method of 
Borisevich et al., (2008).  LLC-MK2 cells in 96-well plates (5x104 per well) were 
infected with 50 µl of serial dilutions of purified SeV (or supernatant from SeV-
infected cells) in DMEM-2.5%.  Cells were incubated at 37°C for two hours to 
allow virus absorption, before being washed in serum-free DMEM.  Cells were 
subsequently incubated overnight in serum-free medium supplemented with 0.3 
µg/ml trypsin.  Twenty hours post-infection, cells were washed with PBS 
containing 1% bovine serum albumin (PBS-1% BSA), and fixed for 30 min at 
4°C with methanol containing 2% H 2O2.  Fixed cells were blocked with PBS-1% 
BSA and stained for expression of SeV F protein with MAb GB5 for 1 h at room 
temperature, followed by incubation with anti-mouse immunoglobin conjugated 
to peroxidase for 30 min at room temperature.  The resulting immune 
complexes were developed using AEC substrate in DMSO (3.3 mg/ml), 
dissolved in a buffer containing 0.1 M citrate, 0.2 M phosphate pH 5.5 and 
0.06% H2O2.  The AEC substrate generates an insoluble precipitate on reaction 
with peroxidase (Graham et al., 1965), resulting in red colouration of infected 
cells that permits their quantification by light microscopy. 
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3.3.2.7 Preparation of cell extracts 
Extracts of membrane proteins from transfected cells were prepared using the 
ProteoExtract® Native Membrane Protein Extraction Kit (Bionova, Calbiochem), 
according to the manufacturer’s instructions.  Briefly, 2x106 cells were 
resuspended in 1 ml extraction buffer and incubated for 15 minutes at 4°C in the 
presence of protease inhibitors.  Following centrifugation, the insoluble pellet 
(enriched in membrane proteins), was resuspended in 0.5 ml of an extraction 
buffer containing detergent for 30 minutes at 4°C, an d clarified by centrifugation.   
 
3.3.3 Nucleic acid techniques 
 
3.3.3.1 Cloning  
The pTM1 plasmid (Elroy-Stein et al., 1989), carrying the full-length cDNA insert 
of the RSV F gene under transcriptional control of the T7 promoter (pTM1-
F_RSV), has been described previously (González-Reyes et al., 2001).   
 
The SeV F and HN genes were amplified from pGEM-F and pGEM-HN 
plasmids with TaqPlus LongTM DNA polymerase (Stratagene), according to the 
manufacturer’s instructions, using G_NcoI+ and G_SpeI- oligonucleotides 
(Table 3.1), and the following PCR program (94ºC, 2 min [94 ºC 30 sec, 45 ºC 1 
min, 72 ºC 5 min] x 25 cycles, 72 ºC 5 min).  Amplified PCR product (50 µl) was 
precipitated by incubation for 1 h at -80ºC with 10 µl sodium acetate and 150 µl 
ethanol.  Precipitated DNA was pelleted by centrifugation (13,000 rpm, 15 min 
at 4ºC) and the pellet was washed with ethanol (75%).  Pellets were dried for 15 
min at RT and resuspended in 50 µl water.  Five micrograms of pTM1, F_SeV 
or HN PCR products were digested with 90 U Nco I (Roche) for 90 min at 37ºC 
and subsequently precipitated, as described above.  A second digestion with 90 
U Spe I (Roche) was carried out by incubation at 37ºC for 90 min, followed by a 
20 min incubation at 65ºC to inactivate Spe I.  Digested pTMI plasmid was 
incubated for 1 h at 37ºC with 2 U shrimp alkaline phosphatase (USB, GE 
Healthcare) to prevent re-circularisation, followed by a 20 min incubation at 
65ºC to inactivate the phosphatase.  Ligation of digested pTM1 plasmid and 
PCR products was carried out for 5 min at a 1:10 ratio using the Roche Rapid 
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Ligation Kit.  E.coli DH5α competent bacteria were transformed with 2 µl ligation 
mix, according to the method described in section 3.3.2.1 and plated onto 
CircleGrow® plates.  Following incubation of plates for 16 h at 37ºC, selected 
colonies were grown in LB medium at 37ºC for 16 h and DNA extracted using 
the Wizard® Plus SV Minipreps DNA Purification System (Promega).  
Subcloning of SeV F and HN genes in pTM1 was confirmed by DNA 
sequencing.  Sequencing reactions were carried out using the Big Dye 3.1 Kit 
(Applied Biosystems), 500 ng of DNA, 30 ng of the sequencing oligonucleotides 
listed in Table 3.1 and the following PCR conditions (94ºC 3 min, [96ºC 30 sec, 
55ºC 4 min] x 25 cycles). 
 
The RSV G gene was subcloned into pTM1 by the same method, with the 
exception that reduced temperatures were employed.  Incubation of 
transformed DH5α bacteria was carried out in LB for 5 h at 25ºC, CircleGrow® 
plates were grown at RT for 4 days, and selected colonies were subsequently 
grown in LB medium at 25ºC for 48 h.  
 
SeV wild-type F (Harris strain) or F_SeV cleavage mutants were cloned into the 
FL5 plasmid by the method above, using F_MluI+ and F_RsrII- oligonucleotides 
(Table 3.1).  According to the “rule of six”, replication of the SeV genome occurs 
efficiently only when the genome is an exact multiple of six nucleotides (Calain 
and Roux 1993). Thus, on replacement of the wild-type F_SeV gene present in 
FL5 with the cleavage site mutants, insertion of 3 nucleotides in the non-coding 
region of SeV (shown in bold in Table 3.1), was required to ensure that the 
length of SeV remained a multiple of six.  F_SeV genes were amplified by PCR 
using the Phusion® High Fidelity DNA polymerase (Finnzymes), according to 
the manufacturer’s instructions, and the following PCR program (98ºC 30 sec 
[98 ºC 15 sec, 65 ºC 30 sec, 72 ºC 4 min] x 30 cycles, 72 ºC 7 min).  Amplified 
PCR products were subsequently digested with Mlu I and Rsr II restriction 
enzymes (Roche) as described above, and ligated with digested FL5 in order to 
replace the wild-type SeV F gene (Z strain) present in FL5.  XL1-Blue 
competent bacteria (Stratagene) were transformed with 5 µl ligation mix, 
according to the method described in section 3.3.2.1, with the exception that 
selected colonies were grown at reduced temperatures (33ºC).  
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3.3.3.2 Mutagenesis 
The pTM1-F_SeV plasmid was subjected to mutagenesis using the 
QuikChange® site directed mutagenesis kit (Stratagene) according to the 
manufacturer’s instructions.  The mutants shown in Figure 4.3 were sequentially 
generated using the corresponding oligonucleotides detailed in Table 3.1 
(section 3.1.6), and the following PCR program (95ºC 30 sec [95 ºC 30 sec, 
55ºC 1 min, 68 ºC 14 min] x 18 cycles).  All mutations were confirmed by 
automated sequencing of the complete F gene, as described in section 3.3.3.1.    
 
3.3.3.3 RNA extraction and RT-PCR 
LLC-MK2 cells were infected in 35 mm dishes with rSeV at an MOI of 0.05 and 
incubated in the presence of 0.3 µg/ml trypsin trypsin for 72 h at 37ºC.  The 
clarified supernatant of infected cells was concentrated 15-fold by centrifugation 
through Vivaspin 2 ml spin columns (Sartorius).  RNA was subsequently 
extracted from concentrated supernatants using the QIAmp Viral RNA Mini Kit 
(Qiagen) according to the manufacturer’s instructions.  In order to amplify the 
complete F_SeV gene, RT-PCR was performed on extracted RNA using the 
FL5+ and HN_274- oligonucleotides (Table 3.1), and the Qiagen OneStep RT-
PCR Kit (50ºC 30 min, 95ºC 15 min [94 ºC 1 min, 55 ºC 1 min, 72 ºC 2 min] x 30 
cycles, 72 ºC 1 min).    
 
3.3.4 Immunochemical techniques 
 
3.3.4.1  Indirect immunofluorescence  
Cells were grown in microchamber culture slides to 90-100% confluence and 
transfected with 0.5 µg total DNA, or infected with MOI 1-5.  Cells were fixed 20-
48 h post-infection with cold (-20ºC) methanol for 5 min, followed by cold (-
20ºC) acetone for 30 seconds.  Fixed cells were immunostained using MAb 
GB5 directed against F_SeV, followed by incubation with anti-mouse FITC-
linked antibody (GE Healthcare UK Limited).  Cells were examined using a 
Zeiss microscope and photographed using an AxioCam HRC digital camera 
and Axiovision 3.1 software.   
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3.3.4.2 Flow cytometry 
Transfected BSR-T7/5 cells were detached 24 h post-transfection using 1 mM 
EDTA in Ca2+- and Mg2+-free PBS, and resuspended in DMEM (2% FCS).  
3x105 cells were incubated for 30 min at 4oC with monoclonal antibody GB5 
(F_SeV) or 2F (F_RSV).  After pelleting and washing the cells two times with 
PBS, cells were stained by subsequent 30 min incubations with biotinylated 
anti-mouse Ig (GE Healthcare UK Limited) and streptavidin-RPE (Southern 
Biotechnology Associates Inc).  Finally, cells were fixed in 1% 
paraformaldehyde and the fluorescence of 2x104 cells determined using a 
Becton Dickinson FACSCalibur instrument with CellQuest software.  Data was 
analysed using Flow Jo software (Tree Star, Inc). 
 
3.3.4.3  Immunoprecipitation and Western blotting 
BSR-T7/5 cells were transfected as previously described in section 3.3.2.3.  
Twenty four hours post-transfection, cells were washed with PBS and extracts 
of membrane proteins prepared using the ProteoExtract® Native Membrane 
Protein Extraction Kit (Calbiochem), as described in section 3.3.2.7.  For the 
immunoprecipitation experiments, purified GB5 antibody was bound to CNBr-
activated Sepharose 4B (Pharmacia), according to the manufacturer’s 
instructions.  1 ml of membrane protein extract was incubated at 4°C with 50 µl 
of GB5-conjugated Sepharose.  After an overnight incubation, Sepharose beads 
were washed four times with PBS, resuspended in 50 µl sample buffer, (80 mM 
Tris, 2% SDS, 10% glycerol and 0.01% bromophenol blue), and boiled for 6 
minutes.  Following centrifugation to remove beads from the eluted proteins, 5% 
β-mercaptoethanol was added and the immunoprecipitated proteins were 
separated on a 10% acrylamide SDS-PAGE gel.  Proteins were transferred to 
an Immobilon membrane (Millipore), and subjected to Western blotting in order 
to detect F_SeV proteins using biotinylated GB5 monoclonal antibody and 
streptavidin-horseradish peroxidase conjugate (GE Healthcare UK Limited).  
Bands were visualised using the Amersham ECL Advance Western Blotting 
Detection Kit (GE Healthcare UK Limited), and imaged using a VersaDoc 
camera and Quantity One 1D analysis software (Bio-Rad Laboratories).   
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Supernatants from infected LLC-MK2 cells were separated on a 10% SDS-
PAGE gel, transferred to an Immobilon membrane (Millipore), and subjected to 
Western blotting using the polyclonal rabbit sera F_RSV_104-117 or F_SeV_CT 
(see section 3.1.5).  Membranes were subsequently incubated with anti-mouse 
immunoglobin conjugated to peroxidase.  Bands were developed using the 
Amersham ECL Advance Western Blotting Detection Kit and imaged using a 
Kodak Gel Logic 1500 Imaging System camera and Kodak Molecular Imaging 
software.  The net intensity of protein bands (indicated in the legend to Fig. 
4.11) was measured using Kodak Molecular Imaging software, and the 
percentage of F protein cleavage to F1 was calculated by dividing the intensity 
of F1 bands by the total net intensity.   
 
3.3.4.4  Enzyme Linked Immunosorbant Assay (ELISA).   
Infected Pro-5 or Lec-2 cells (MOI 1) growing in 96-well microtitre plates were 
washed 20 h post infection with PBS containing 0.05% Tween-20 (PBS-Tween, 
Bio-Rad Laboratories) and fixed in 80% acetone.  The wells were blocked for 30 
min at room temperature with 5% pig serum in 0.05% PBS-Tween.  Cells were 
subsequently stained for expression of SeV F protein with MAb GB5 for 1h at 
room temperature, followed by incubation with anti-mouse Ig conjugated to 
horseradish peroxidase (GE Healthcare UK Limited) for 45 min at room 
temperature.  Optical density at 490 nm was measured after the addition of the 
substrate o-phenylene diamine (OPD), dissolved in a buffer containing 0.1 M 
citrate, 0.2 M phosphate pH 5.5 and 0.06% H2O2. 
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3.3.5 Fusion assays 
 
3.3.5.1 Syncytium formation assay 
The size of syncytia in infected LLC-MK2 cells growing in microchamber slides 
(see section 3.3.4.1) was measured by counting the number of nuclei in 10 
syncytia selected at random from distinct 20x magnification fields.  For the 
experiment shown in Fig. 4.15, LLC-MK2 cells were pre-treated prior to infection 
with 120 mU neuraminidase from Clostridium perfringens (Sigma) in OptiMEM 
medium (Gibco) for 90 min at 37ºC.  The level of infection in the absence or 
presence of neuraminidase was determined by counting the number of infected 
cells in five 20x magnification fields selected at random.   
 
3.3.5.2 Luciferase reporter gene assay 
BSR-T7/5 cells were transfected in 48-well plates with 0.5 µg total DNA.  BHK 
cells in 100 cm dishes were simultaneously transfected with 30 µg of a plasmid 
encoding the luciferase gene (pTM1-Luc).  For the cell-cell fusion assay, BHK 
cells were detached 7 h post-transfection using 1 mM EDTA in Ca2+- and Mg2+-
free PBS, resuspended at a density of 1x106 cells/ml in serum-free medium, 
and overlaid at a 1:1 ratio onto BSR cells,  either in the presence or absence of 
0.25 µg/ml trypsin (Sigma). The mixed donor and target cells were subsequently 
incubated at 37ºC to allow fusion.  At 30 h post-transfection, (or 48 h post 
transfection for experiments involving F_RSV), cells were washed with PBS and 
lysed in 1x Passive Lysis Buffer (Promega Inc), according to the manufacturer’s 
instructions.  10-20 µl of clarified cell extract were mixed with 100 µl luciferase 
assay substrate (Promega Inc), and immediately assayed for luciferase activity 
over a 10 second measurement read using a Turner Biosystems 20/20n 
Luminometer instrument.  Background activity (subtracted from all results 
shown), was determined by overlaying BHK cells transfected with pTM1-Luc 
onto BSR cells, which had previously been transfected with the pTM1 plasmid. 
 
Alternatively, BSR-T7/5 cells were infected in DMEM-2.5% at an MOI of 5 and 
incubated at 37°C for two hours.  BSR-T7/5 cells were subsequently washed in 
serum-free DMEM and incubated for 14 h in serum-free medium supplemented 
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with or without 0.25 µg/ml trypsin.  LLC-MK2 cells in 100 cm dishes were 
transfected (FuGENE® HD, Roche) with 30 µg of a plasmid encoding the 
luciferase gene (pTM1-Luc), and incubated at 37°C for 1 4 h in DMEM-2.5%.  
For the cell-cell fusion assay, LLC-MK2 cells were detached 14 h post-
transfection using 1 mM EDTA in Ca2+- and Mg2+-free PBS, resuspended at a 
density of 1x106 cells/ml in serum-free medium, and overlaid at a 1:1 ratio onto 
BSR-T7/5 cells,  either in the presence or absence of 0.25 µg/ml trypsin 
(Sigma).  Mixed donor and target cells were incubated for 3 h at 33°C or 37°C 
to allow fusion.  Cells were subsequently washed with PBS, lysed in 1x Passive 
Lysis Buffer and processed for measurement of luciferase activity, as described 
above. 
 
3.3.5.3  Haemolysis   
Guinea pig erythrocytes were washed three times with PBS (5 min, 2000 rpm), 
and resuspended in PBS (1% vol/vol).  For the haemolysis experiments, purified 
SeV (5x108 ffu) was incubated at 33°C for 45 min with 0.5 ml wa shed guinea 
pig erythrocytes.  Haemolysis was measured by determining the optical density 
of the erythrocyte supernatant at 520 nm.   
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4.  RESULTS 
 
4.1  Comparison of the fusion requirements for Sendai virus and 
respiratory syncytial virus glycoproteins 
 
4.1.1  Cloning and expression of Sendai virus and respiratory syncytial 
virus glycoproteins 
 
The gene encoding the RSV fusion protein (F_RSV) has been previously 
subcloned into the pTM1 expression vector (González-Reyes et al., 2001).  The 
genes encoding the SeV fusion (F_SeV) and attachment (HN) proteins were 
thus subcloned from the pGEM-4 expression vector into pTM1.  The pTM1 
vector (Fig. 4.1A) permits expression of the cloned gene of interest under 
transcriptional control of the T7 bacteriophage promoter (Elroy-Stein et al., 
1989).  In addition, pTM1 contains the encephalomyocarditis virus (ECMV) 
untranslated region (5’ UTR), situated immediately downstream of the T7 
promoter.  The ECMV UTR results in increased efficiency of translation of T7-
driven transcripts by a cap-independent mechanism, resulting in increased 
expression of the cloned gene of interest (Moss et al., 1990).  Subcloning of 
SeV F and HN genes was carried out as described in the Materials and 
Methods.   Expression of SeV pTM1-F and pTM1-HN plasmids (Fig. 4.1B) was 
confirmed by immunofluoresence of transfected BSR-T7/5 cells (a BHK-derived 
cell line that constitutively express T7 RNA polymerase) at 24 h post-
transfection, using antibodies directed against the F protein (monoclonal 
antibody GB5), or HN protein (rabbit polyserum HN_SeV_CT).   
 
Similarly, the gene encoding the RSV attachment (G) glycoprotein was 
subcloned into pTM1.  However, as detailed in the Materials and Methods, it 
was necessary to lower the temperatures at which competent bacteria were 
grown.  Expression of pTM1-G (Fig. 4.1B) was subsequently confirmed by 
immunofluoresence of transfected BSR-T7/5 cells at 48 h post-transfection, 
using monoclonal antibody (63G) against the G protein (Garcia-Barreno et al., 
1992). 
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Figure 4.1.  Cloning and expression of Sendai virus and respiratory syncytial virus 
glycoproteins. 
(A) Schematic diagram of the pTM1 plasmid.  The T7 promoter is shown as a blue arrow and 
the ampicillin resistance gene (AmpR) as a red arrow.  Also indicated is the ECMV UTR (green), 
and the multiple cloning site (MCS), with restriction enzymes used for subcloning of the 
paramyxovirus genes highlighted in red.  (B) Expression of cloned glycoproteins in transfected 
BSR-T7/5 cells was detected using monoclonal antibodies against the SeV F protein (GB5), 
RSV G protein (63G), or a polyclonal rabbit serum raised against the SeV HN protein 
(HN_SeV_CT). 
 
4.1.2  Comparison of the requirements of respiratory syncytial virus and 
Sendai virus fusion proteins for cell-cell fusion   
 
It has previously been reported that RSV F protein (F_RSV) is able to fuse cells 
when expressed in transfected cells in the absence of the attachment G protein 
(González-Reyes et al., 2001; Zimmer et al., 2001a).  In contrast, SeV F protein 
(F_SeV) requires both trypsin and co-expression of the attachment HN protein 
in order to fuse cell membranes (Tanabayashi and Compans 1996).  Thus, we 
aimed to confirm the distinct requirements for cell-cell fusion of RSV and SeV F 
proteins.  BSR-T7/5 cells were transfected with pTM1 plasmids containing RSV 
A
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or SeV glycoproteins, and incubated in the absence or presence of 0.25 µg/ml 
trypsin for 32 h (F_SeV), or 48 h (F_RSV).  Fixed BSR-T7/5 cells were 
subsequently immunostained using monoclonal antibodies directed against 
F_SeV or F_RSV
 
proteins (Fig. 4.2A).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.  RSV and SeV fusion proteins have different requirements for cell-cell fusion.   
(A) BSR-T7/5 cells were transfected in microchamber culture slides with pTM1 plasmids pTM1-
F_RSV or pTM1-F_SeV and pTM1-G or pTM1-HN plasmids, as indicated.  The transfection 
mixture was removed 7 h post-transfection and cells were incubated in serum-free medium with 
(+) or without (-) trypsin.  Cells were fixed 32 h post transfection (SeV) or 48 h post transfection 
(RSV), and immunostained as indicated in the Materials and Methods.  Syncytia are indicated 
by arrows for F_SeV.  (B)  BSR-T7/5 cells in 48-well plates were transfected with plasmids 
encoding RSV or SeV genes.  BHK cells were simultaneously transfected with a plasmid 
encoding the luciferase gene (pTM1-Luc).  Seven hours post-transfection, BHK cells were 
detached, resuspended at a density of 1x106 cells/ml in serum-free medium, and overlaid at a 
1:1 ratio onto BSR cells, either in the presence or absence of trypsin.  At 30 h post-transfection 
(or 48 h post transfection for experiments involving F_RSV), cells were lysed and analysed for 
luciferase activity.  Results (relative light units) are expressed as a percentage of wild-type (wt) 
fusion (F_SeV + HN + trypsin or F_RSV + G + trypsin).  Mean values from three independent 
experiments are shown.   
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Formation of syncytia (multinuclear, fused cells) was observed in transfected 
cells that expressed F_RSV as the only viral protein, both in the absence and 
presence of trypsin.  The number and size of syncytia was enhanced by co-
expression of F_RSV with the attachment G protein, and by the presence of 
trypsin in the culture medium.  In contrast, F_SeV displayed a strict requirement 
for both HN co-expression and trypsin for syncytia formation.  
 
The results of the syncytium formation assay were confirmed by a quantitative, 
luciferase reporter gene fusion assay (Fig. 4.2B).  BSR-T7/5 cells transfected 
with the viral genes of interest were mixed with BHK cells, which had been 
previously transfected with the pTM1-Luc plasmid, and left to fuse in the 
absence or presence of trypsin.  Since pTM1-Luc contains the luciferase 
reporter gene under transcriptional control of the T7 promoter, expression of 
luciferase only takes place in BHK cells that have fused with BSR-T7/5 cells 
(that constitutively express T7 RNA polymerase), thus permitting quantitative 
measurement of cell-cell fusion.  While trypsin produced only a moderate 
enhancement in the level of fusion induced by F_RSV, co-expression of G 
increased cell-cell fusion by approximately two-fold.  Therefore, while not a strict 
requirement, G enhances F_RSV-mediated cell-cell fusion.  In contrast, and in 
accordance with the syncytium formation assay, F_SeV required both HN co-
expression and trypsin in order to produce significant cell-cell fusion.     
 
4.2   Generation and expression of Sendai virus fusion protein cleavage 
site mutants 
 
4.2.1  Construction of Sendai virus fusion protein cleavage site mutants  
 
In addition to their distinct requirements for cell-cell fusion, a comparison of the 
primary structure of RSV and SeV F proteins reveals some key differences.  
SeV F protein contains a single arginine residue at its cleavage site (R116), 
thereby necessitating the addition of trypsin to cell culture medium for F protein 
cleavage.  In contrast, RSV F possesses two furin-consensus cleavage sites 
(site I RARR109 and site II KKRKR136), which are separated by a region of 27 
amino acids (pep27).  Alignment of F_RSV and F_SeV primary sequences (Fig. 
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4.3) reveals that although both proteins have homologous fusion peptides, the 
two multibasic cleavage sites and the intervening segment of F_RSV cannot be 
aligned with F_SeV, resulting in a gap in the alignment.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Schematic diagram of SeV F protein cleavage site mutants.  Alignment of 
F_RSV (amino acids 100-144, red) and F_SeV (amino acids 99-129, blue), with gaps in the 
alignment indicated by dashed lines.  Cleavage sites of F_RSV
 
(site I, RARR109 and site II, 
KKRKRR136) and F_SeV (R116) are shown in bold and indicated by arrows.  The fusion 
peptide is located immediately proceeding the cleavage site.  Residues from F_RSV that were 
inserted into a backbone of F_SeV are shown in red.   
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Thus, we aimed to investigate if the unique characteristics of the F_RSV 
proteolytic processing region play a role in the distinct fusion requirements by 
F_RSV and F_SeV.  Site-directed mutagenesis was carried out on the pTM1-
F_SeV plasmid in order to reproduce partially, or totally, the sequences that 
determine cleavage of F_RSV
.
  In an initial round of mutagenesis, residues from 
the second cleavage site of F_RSV were inserted directly preceding the single 
cleavage site of F_SeV
 
(R116), producing F_RKR and F_KKRKR mutants, 
containing a minimal furin recognition sequence (RKRR), or the complete 
F_RSV cleavage site II (KKRKRR), respectively (Fig. 4.3).  The F_KKRKR 
mutant was termed F_cleavage (Fc), and was subjected to further mutation in 
order to introduce F_RSV cleavage site I, producing the F110 mutant.  As 
detailed in Fig. 4.3, the complete intervening sequence between the two RSV F 
cleavage sites (pep27) was then inserted into the F110 mutant in three stages.  
F117 contains both F_RSV cleavage sites I and II, separated by 27 intervening 
amino acids derived from both F_RSV and F_SeV.   F∆ was subsequently 
produced from the F117 mutant by a deletion N-terminal to the second cleavage 
site, resulting in a shortened intervening segment, composed entirely of F_RSV 
residues.  Finally, the remaining residues of F_RSV pep27 were inserted into 
F∆ to produce the F130 mutant, which contains the complete F_RSV pep27 
sequence. 
 
4.2.2  Expression of Sendai virus fusion protein cleavage site mutants in 
transfected cells  
 
The relative cell surface expression levels (in comparison to wild-type F_SeV) 
of the distinct F_SeV cleavage mutants was determined by flow cytometry of 
transfected BSR-T7/5 cells, using the monoclonal antibody GB5 directed 
against F_SeV.  All F_SeV cleavage site mutants were expressed at the cell 
surface at levels comparable to the wild-type (wt) F_SeV protein (Fig. 4.4A), 
although a slight decrease in expression was noted for F_SeV mutants 
containing both F_RSV cleavage sites.  Expression was also analysed by 
immunoprecipitation of transfected cell extracts in order to compare proteolytic 
cleavage of the mutant SeV F proteins.  Monoclonal antibody GB5 was purified 
by affinity chromatography and conjugated to Sepharose 4B beads, which were 
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used to immunoprecipitate SeV F proteins from membrane extracts of 
transfected BSR-T7/5 cells.  The resulting immunoprecipitates were separated 
by SDS-PAGE, and visualised by Western blot using biotinylated GB5 antibody 
and a streptavidin-PO conjugate.   
 
In the absence of trypsin, both F_SeV wild-type and the single cleavage site 
mutant F_RKR remained essentially uncleaved, as only a faint band 
representing cleaved F1 was observed (Fig. 4.4B, upper panel).  In contrast, the 
Fc mutant and double cleavage site mutants F110, F117 and F130 were 
cleaved to a greater extent in the absence of trypsin.  A band migrating at a 
lower molecular weight than F0 was observed for the mutant F∆.  Although the 
identity of this band has not been thoroughly investigated, it may represent the 
F0 precursor of the F∆ mutant, which lacks an N-glycosylation site that has 
previously been shown to be used in the Z strain of SeV F protein (N104), 
(Segawa et al., 2000).  On the addition of trypsin to the culture medium of 
transfected cells (Fig. 4.4B, lower panel), cleavage of all F proteins was 
enhanced.  In particular, double cleavage site F_SeV mutants were almost 
completely cleaved to F1, as only a faint band corresponding to uncleaved F0 
was seen.  Thus, insertion of F_RSV cleavage site II in SeV F protein increases 
the extent of cleavage at this site in the absence of trypsin.  The susceptibility of 
site II to trypsin cleavage is further enhanced by insertion of F_RSV cleavage 
site I upstream of site II, as observed for the double cleavage site mutants.   
 
It has previously been shown that in the absence of cleavage at site II, cleavage 
of F_RSV at site I results in a partially-cleaved protein (F1+), seen as an 
intermediate band between F0 and F1 (González-Reyes et al., 2001).  
However, F1+ was not observed for the F_SeV double cleavage site mutants, 
suggesting that site I is either not cleaved, or that if cleavage at site I does take 
place, it is immediately proceeded by cleavage at site II to form F1.  Similarly, 
König et al., (2004) also failed to observe the presence of F1+ in transfected 
cells, suggesting that the ability to observe this partially-cleaved intermediate is 
dependent on cell type and/or expression system.  
 
 
Results 
 
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Cell surface expression and proteolytic cleavage of chimeric SeV F mutants.  
(A) Cell surface expression levels of wild-type and mutant F_SeV proteins were determined by 
flow cytometry analysis of transfected BSR-T7/5 cells 24 h post-transfection, using the 
monoclonal antibody GB5.  The mean fluorescent intensity of cells is represented as a 
percentage of wild-type F_SeV expression, and mean values from three independent 
experiments are shown. (B) Extracts of membrane proteins were prepared from transfected 
BSR-T7/5 cells incubated in the absence (upper panel) or presence (lower panel) of trypsin, and 
subjected to immunoprecipitation using purified GB5 antibody bound to Sepharose beads.  The 
immunoprecipitated F_SeV proteins were subsequently fractionated by SDS-PAGE under 
reducing conditions, and analysed by Western blotting using biotinylated GB5 antibody and a 
streptavidin-horseradish peroxidase conjugate.   
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4.3  Effect of cleavage site mutants on the ability of paramyxovirus 
fusion proteins to direct cell-cell fusion  
 
4.3.1  Formation of syncytia in the absence or presence of the HN 
attachment protein by Sendai virus fusion protein cleavage site mutants  
 
Syncytium formation by F_SeV cleavage mutants was tested by transfection of 
BSR/T7-5 cells with F_SeV mutants in the absence or presence of HN co-
expression.  In the presence of the HN attachment protein, only small syncytia 
were observed for F_RKR when trypsin was excluded from the culture medium, 
as indicated by the arrows in Fig. 4.5A, reflecting the poor cleavage of F_RKR 
in the absence of trypsin (Fig. 4.4B).  In contrast, Fc formed large syncytia in 
the absence of trypsin (Fig. 4.5A), consistent with the enhanced cleavage of the 
Fc mutant (Fig. 4.4B).  However, although Fc was capable of forming more 
extensive syncytia than wt F_SeV, (compare with Fig. 4.2), both single cleavage 
site F_RKR and Fc mutants continued to require HN co-expression in order to 
form syncytia, since only individual, unfused cells were observed in the absence 
of HN co-expression (Fig. 4.5B).  Double cleavage site F_SeV mutants formed 
extremely large syncytia in the presence of HN, without a requirement for 
trypsin (Fig. 4.5A).  Moreover, and in contrast to single cleavage site mutants, 
all double cleavage site F_SeV mutants were also able to form syncytia in the 
absence of HN co-expression (Fig. 4.5B). Therefore, inclusion of the two 
multibasic F_RSV cleavage sites in F_SeV facilitates syncytium formation in the 
absence of an attachment protein, thus mimicking the unique properties of 
F_RSV.  Although HN-independent cell-cell fusion was observed in the absence 
of trypsin, trypsin inclusion did enhance the size and number of syncytia 
formed.  The ability of the F110 mutant to form syncytia in the absence of HN 
implies that insertion of both F_RSV cleavage sites and not the intervening 
pep27 sequence per se conveys HN-independence for cell-cell fusion.  
However, the sequence and/or length of the intervening region between the two 
cleavage site does appear to influence the extent of fusion, since F117 forms 
larger syncytia than F∆ in the absence of HN (Fig. 4.5B).     
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Figure 4.5. Syncytium formation by Sendai virus F protein cleavage site mutants.  BSR-
T7/5 cells growing in microchamber wells were transfected with pTM1 plasmids encoding wt or 
mutant F_SeV genes with (A) or without (B) pTM1-HN.  Transfected cells were processed for 
syncytia formation 32 h post-transfection, as described in the legend to Fig. 4.2A.   
 
4.3.2  Cell content mixing in the absence or presence of the HN 
attachment protein by Sendai virus fusion protein cleavage site mutants  
 
In order to confirm the results of the syncytium formation assay, all of the 
mutants detailed in Fig. 4.3 were analysed for cell content mixing using the 
luciferase reporter gene assay (Fig. 4.6).  Luciferase activity was expressed as 
a percentage of fusion relative to wt F_SeV co-expressed with HN in the 
presence of trypsin, which represents 100% fusion. As shown in Fig. 4.6A, the 
F
_
RKR mutant produced only 50% of wt fusion in the absence of trypsin, and 
fused cells to the same extent as the wt F protein on addition of trypsin.  In 
contrast, Fc produced 181% of wild-type F_SeV fusion in the absence of 
trypsin.  Thus, the presence of six basic residues at the cleavage site of F_SeV 
enhances the fusogenic potential of this protein when co-expressed with HN, in 
the absence or presence of trypsin.  In the presence of HN, all double cleavage 
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site F_SeV mutants displayed dramatically increased fusion with respect to the 
wt F protein (between three- and four-fold in the presence of trypsin), with the 
intervening sequence between the two cleavage sites exerting a minor, 
modulatory role on fusion.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Cell-cell fusion by Sendai virus F protein cleavage site mutants.  BSR-T7/5 
cells were transfected with pTM1 plasmids encoding wt or mutant F_SeV genes with (A) or 
without (B) pTM1-HN, as indicated.  Cells were mixed with BHK cells, which had previously 
been transfected with pTM1-Luc, either in the presence or absence of trypsin, and incubated for 
22 h to allow fusion.  Cells were subsequently lysed and analysed for luciferase activity at 30 h 
post-transfection.  Results (relative light units), are expressed as a percentage of wt fusion 
(F_SeV + HN + trypsin), with mean values from three independent experiments shown.   
 
F1
30
F_
Se
V
F_
R
KR F
c
F1
10
 
F1
17 F∆
F_
Se
V
F_
R
KR Fc
F_
Se
V
+
 
H
N
 
F1
30
F1
10
 
F1
17 F∆
A
B 
0
100
Fu
si
o
n
(%
 
w
t)
200
300
400
500
600
0
20
40
60
80
100
120
Fu
si
o
n
(%
 
w
t)
- Trypsin
+ Trypsin
+ HN
- HN
Results 
 
74 
In the absence of HN co-expression (Fig. 4.6B), three double cleavage site 
mutants (F110, F117 and F130) produced fusion activity in the luciferase 
reporter gene assay in the presence of trypsin.  As observed in the syncytium 
formation assay, the single cleavage site Fc mutant did not produce significant 
fusion in the absence of HN.  The F∆ double cleavage site mutant also failed to 
produce HN-independent fusion in the reporter gene assay, reflecting the small 
syncytia produced by this mutant in the absence of an attachment protein (Fig. 
4.5B).   
 
The enhanced fusogenicity of double cleavage site mutants may reflect their 
increased susceptibility to cleavage in the presence of trypsin (Fig. 4.4B, lower 
panel).  However, no strict correlation between F0 processing and membrane 
fusion activity was observed.  For instance, while F∆ was highly susceptible to 
trypsin cleavage, this mutant was poorly active in membrane fusion assays.  
Furthermore, although F130 was cleaved by trypsin more efficiently than F110 
or F117 mutants (Fig. 4.4B, lower panel), it did not produce larger syncytia or 
induce greater luciferase activity in the absence of HN (Figures 4.5 and 4.6).  
 
Lower levels of HN-independent fusion were observed for the double cleavage 
site mutants in the luciferase reporter gene assay compared to the syncytium 
formation assay.  This may reflect differences in the requirements of the two 
assays.  For instance, the presence of F protein in both target and donor cells in 
the syncytium formation assay may facilitate cell-cell fusion with respect to the 
reporter gene assay, in which F protein is present only in the donor BSR-T7/5 
cells.  Furthermore, the reporter gene assay involves the interaction between 
two distinct populations of cells, and may depend to a greater extent on the 
attachment ability of the mutated F proteins.   
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4.3.3  Cell content mixing in the absence or presence of the G attachment 
protein by respiratory syncytial virus fusion protein cleavage site mutants  
 
It has previously been shown that cleavage at both sites I and II is a 
requirement for fusion of the RSV F protein in the absence of the attachment G 
protein.  Mutations of F_RSV cleavage site I abrogated syncytia formation in the 
absence of trypsin, whereas deletion of F_RSV cleavage site II prevented 
syncytia formation, even in the presence of trypsin (González Reyes et al., 
2001; Zimmer et al., 2001a). In light of our findings that insertion of F_RSV 
cleavage site I in F_SeV led to syncytia formation by F_SeV in the absence of 
HN, we aimed to determine whether co-expression of RSV G protein with 
F_RSV cleavage site mutants would restore cell-cell fusion.   
 
A series of F_RSV cleavage site mutants (Fig. 4.7A) have been previously 
described (González Reyes et al., 2001; Ruiz-Argüello et al., 2002; 2004).  
These mutations included changes in cleavage site I (RARR) to produce the 
F_R108/109N mutant (RANN), or deletion of four basic residues of cleavage 
site II (KKRKRR), resulting in the F_∆131-134 mutant (González Reyes et al., 
2001).  Deletion of part or all of the intervening pep27 sequence of F_RSV 
resulted in the RSV F_∆108-120 and F_∆108-132 mutants, respectively (Ruiz-
Argüello et al., 2002; 2004).  All mutant proteins were expressed at the cell 
surface at levels comparable to F_RSV, as determined by flow cytometry of 
transfected cells (Fig. 4.7B), with the exception of the cleavage site II mutant 
F_∆131-134, which was expressed at a reduced level (60% of wild-type 
F_RSV).  This is consistent with previous findings that mutation of F_RSV 
cleavage site II increases the susceptibility of the protein to degradation, 
suggesting that mutation of site II affects the conformation of F_RSV (Zimmer et 
al., 2001a).   
 
The cell-cell fusion activity of F_RSV cleavage mutants was analysed by the 
luciferase fusion assay (Figures 4.7C and 4.7D).  Cleavage site I mutant 
F_R108/109N produced a low level of fusion, which was increased by the 
presence of trypsin, but not by co-expression of the G protein.  Cleavage site II 
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mutant F_∆131-134 failed to produce fusion above background levels, 
irrespective of the inclusion of trypsin or G protein.  Further mutation of F_RSV 
by deletion of pep27 to produce F_∆108-120 and F_∆108-132 mutants led to an 
increase in cell-cell fusion activity compared to F_R108/109N, in particular in 
the presence of the attachment G protein.  However, the fusion activity of both 
F_∆108-120 and F_∆108-132 in the presence of G was approximately half that 
of the wild-type, (54% and 49% of wt F co-expressed with G in the presence of 
trypsin, respectively).  Therefore, co-expression of the G protein failed to fully 
rescue the reduced fusogenic capacity of the RSV F cleavage site mutants.     
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Figure 4.7. Cell-cell fusion by RSV F cleavage site mutants. (A) The amino acid sequence 
surrounding the F_RSV proteolytic processing region (amino acids 103 to 141) is shown. 
F_RSV cleavage sites (site I, RARR109 and site II, KKRKRR136) are shown in bold and 
indicated by arrows.  Deleted residues are shown by a dashed line. (B) The level of cell surface 
expression of wild-type (wt) and mutant F_RSV proteins was determined by flow cytometry of 
transfected BSR-T7/5 cells 24 h post-transfection, using the monoclonal antibody 2F.  The 
mean fluorescent intensity of cells is represented as a percentage of wt F_RSV expression, with 
mean values from three independent experiments shown. (C) BSR-T7/5 cells were 
cotransfected in 48-well plates with pTM1 plasmids encoding wt or mutant F_RSV genes in the 
absence (-G) or presence (+G) of pTM1-G.  BHK cells were simultaneously transfected with 
pTM1-Luc and overlaid at a 1:1 ratio onto BSR-T7/5 cells.  Cells were lysed and analysed for 
luciferase activity at 48 h posttransfection.  Results (relative light units) are expressed as a 
percentage of wt fusion (F_RSV + G + trypsin), with mean values from three independent 
experiments shown. 
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4.4   Generation and expression of recombinant Sendai viruses 
containing fusion protein cleavage site mutations 
 
4.4.1   Subcloning of Sendai virus fusion protein cleavage site mutants in 
the full length Sendai virus cDNA plasmid 
 
Given the previously described differences between paramyxovirus cell-cell and 
virus-cell fusion (Connolly and Lamb 2007), it was of interest to analyse the 
effect of F_SeV cleavage site mutations on fusion and infection by Sendai virus.  
To this aim, recombinant Sendai virus (rSeV) was generated from a cDNA clone 
(FL5).  As shown in Fig. 4.8A, FL5 is an 18.3 kb plasmid that contains the full 
length SeV cDNA (Z strain) and various unique restriction enzyme sites.  The 
genes encoding wild-type SeV F from the Harris strain (FH), and SeV cleavage 
mutants Fc, F110, F117 and F130 (see Fig. 4.9A), were subcloned from pTM1 
into the FL5 plasmid between the Mlu I and Rsr II restriction sites, replacing the 
wild-type SeV F gene (Z strain) present in FL5.  (see section 3.3.3.1 and Table 
3.1 of the Materials and Methods for details of the subcloning protocol and 
oligonucleotides employed).   
 
4.4.2 Rescue of recombinant Sendai virus containing mutations at the 
fusion protein cleavage site 
 
The minimal infectious unit of negative-strand RNA viruses is the 
ribonucleoprotein complex (RNP), which comprises nuclear (N), phosphoprotein 
(P), and large RNA-dependent RNA polymerase (L) proteins.  Thus, in order to 
rescue rSeV, BSR-T7/5 cells that constitutively express T7 polymerase were 
co-transfected with FL5 cDNA and pTM1 plasmids carrying the N, P and L 
genes under transcriptional control of the T7 promoter (Fig. 4.8B).  Transcription 
of transfected plasmids results in the production of antigenomic (+) RNP, thus 
permitting the assembly of genomic (-) RNP after one successful round of 
replication driven by the plasmid-encoded support proteins (for a review, see 
Conzelmann 1998).   
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Figure 4.8. Outline of the rescue of recombinant Sendai virus.  (A) The plasmid (FL5) 
encoding the full length cDNA Sendai virus genome is shown (drawn using pDRAW32 1.1.105 
DNA analysis software).  Sendai virus genes are indicated by arrows, and unique restriction 
sites Mlu I and Rsr II employed in the subcloning of F_SeV genes are shown. (B) In order to 
rescue recombinant SeV from the FL5 cDNA clone, BSR-T7/5 cells that constitutively express 
T7 polymerase were co-transfected with FL5 and pTM1 plasmids carrying the N, P and L genes 
under transcriptional control of the T7 promoter.  Cells were harvested 72 h post transfection 
and injected into 9-day-old embryonated chicken eggs, which permit the growth of SeV to high 
titres (Garcin et al., 1995).  RNP; ribonucleoprotein complex. 
A
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Transfected BSR-T7/5 cells were incubated in the absence or presence of 
trypsin at 33°C for 72 h and the cell culture supernata nt was subsequently 
passaged three times in 9-day-old embryonated chicken eggs to increase viral 
yield (Garcin et al., 1995).  In order to detect the presence of viral proteins, 
allantoic fluid was pelleted through a 25% glycerol cushion for 30 min at 15,000 
rpm and loaded onto a 10% SDS-PAGE gel.  As seen in Fig. 4.9B, all rSeV 
(SeV-FH, SeV-Fc, SeV-F117 and SeV-F130) were successfully rescued.  
However, titration of the allantoic fluid by the method of Borisevich et al., (2008), 
revealed that double cleavage site mutants SeV-F117 and SeV-F130 were 
attained at lower titres than single cleavage site mutants SeV-FH and SeV-Fc, 
as detailed in the legend of Fig. 4.9B.  Whether these differences reflect lower 
replication or lower efficiency of rescue of the double cleavage site viruses 
compared with single cleavage site viruses is not known at present. The band 
representing the M protein appears fainter and additional bands are present for 
the double cleavage site mutants, in particular for F117.  This may reflect 
degradation of purified virus on SDS-PAGE sample preparation or the presence 
of contaminating bands from the allantoic fluid on virus purification.  Sequencing 
of RT-PCR products confirmed that the F and HN genes had not acquired 
spurious mutations during the rescue (not shown). 
 
F protein expression by rSeV was confirmed by Western blotting with a 
polyclonal serum directed against the cytoplasmic tail (CT) of F_SeV (Fig. 
4.9C).  Faint bands migrating with a size corresponding to F0 were observed 
only for single cleavage site FH and Fc mutants, suggesting that almost 
complete cleavage of the F proteins to F1 had taken place.  It is likely that 
trypsin-like endoproteases present in embryonated chicken eggs are 
responsible for cleavage of the F protein (Gotoh et al., 1990; Muramatsu and 
Homma 1980).   
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Figure 4.9. Rescue of recombinant Sendai viruses (rSeV).  (A)  Alignment of SeV fusion 
protein (F_SeV), (amino acids 99-129, blue) and RSV fusion protein (F_RSV), (amino acids 
100-144, red).  Cleavage sites of F_RSV (site I, RARR109 and site II, KKRKRR136) and F_SeV 
(R116) are shown in bold and indicated by arrows.  Residues from F_RSV that were inserted 
into the F_SeV backbone to produce cleavage mutants are shown in red.  Recombinant Sendai 
virus expressing the F protein mutants was rescued by co-transfection of BSR-T7/5 cells with 
the FL5 plasmid containing the complete SeV cDNA and pTM1 plasmids encoding SeV N, P 
and L genes.  Rescued virus was subsequently passaged three times in embryonated chicken 
eggs.  Titration of the allantoic fluid revealed that double cleavage site viruses were obtained at 
lower titres compared to single cleavage site viruses (SeV-FH: 5x1011, Fc: 9x1011, F117: 9x1010, 
F130: 5x1010).  Allantoic fluid from the third passage in eggs was clarified, centrifuged through a 
25% glycerol cushion, and equivalent infectious titres of SeV-FH, SeV-Fc, SeV-F117 and SeV-
F130 were analysed on a 10% SDS-PAGE gel stained with Coomassie blue (B) or by Western 
blotting (C) using the polyclonal rabbit serum (F_SeV_CT), which recognises the cytoplasmic 
tail of F_SeV. (P, phosphoprotein; HN, haemagglutinin-neuraminidase; N, nucleoprotein; M, 
matrix protein; F0, uncleaved F protein precursor; F1, cleaved F protein). 
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4.4.3   Titration and growth of recombinant Sendai virus  
 
In order to compare the growth of rSeV over multiple replication cycles, LLC-
MK2 cells were infected with rSeV at a low multiplicity of infection (MOI) of 0.05 
and incubated in the absence or presence of trypsin for 96 h.  At 24 h intervals, 
aliquots of cell culture supernatant were taken and replaced with fresh medium, 
with or without trypsin.  Titration of the culture supernatant was performed by 
immunohistochemical staining of infected LLC-MK2 cell foci in 96-well plates 
(Borisevich et al., 2008).  As can be seen from Fig. 4.10, wt SeV-FH virus 
required the presence of trypsin in order to replicate, consistent with previously 
published findings that SeV requires trypsin for F protein cleavage (Scheid and 
Choppin 1974).   
 
In contrast, all of the F protein cleavage mutants replicated to high titres both in 
the absence or presence of trypsin, although viruses grew to higher titres 
(approximately one logarithm) in the presence of trypsin (Fig. 4.10B).  While all 
of the mutants reached titres comparable to wt SeV-FH at 96 h post-infection, 
the double cleavage site mutants displayed slightly faster replication kinetics 
during the first 48 h of infection.  This difference in replication kinetics was 
further enhanced when virus was grown at 33°C, with d ouble cleavage site 
mutants replicating to titres at least one logarithm higher than single cleavage 
site viruses during the first 48 h of infection (Table 4.1).  Therefore, insertion of 
both F_RSV cleavage sites in SeV F protein leads to faster replication kinetics 
in infected cells during the first 48 h of replication, in particular at 33°C, but does 
not alter the overall titres obtained after 96 h.   
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Figure 4.10. Multistep growth curve.  LLC-MK2 cells were infected with an MOI of 0.05 and 
incubated in the absence (A) or presence (B) of trypsin for 96 hours.  At 24 h intervals, aliquots 
of the cell culture supernatant were collected and replaced with fresh medium with or without 
trypsin.  Titration of the culture supernatant was performed by immunohistochemical staining of 
infected LLC-MK2 cell foci in 96-well plates.  Results represent the mean of two independent 
infections, which were titrated in duplicate. Ffu, focus forming units. 
 
 
Table 4.1.  Titration of rSeV 48 h post-infection. 
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4.4.4 Proteolytic cleavage of recombinant Sendai virus 
 
Proteolytic processing of the distinct F_SeV cleavage mutants was compared 
by infection of LLC-MK2 cells with an MOI of 0.05.  Cells were incubated in the 
absence or presence of trypsin for 4 days and fresh trypsin was added to the 
cell culture medium every 24 h.  Cell culture supernatant was subsequently 
analysed by Western blotting with a polyclonal serum (F_SeV_CT), directed 
against the cytoplasmic tail of F_SeV (Fig. 4.11, upper panel).  A band 
representing wild-type FH was not observed in the absence of trypsin (Fig. 4.11, 
upper-left panel), reflecting the inability of SeV-FH to grow in the absence of 
trypsin (Fig. 4.10).  The single cleavage site mutant Fc was present in 
uncleaved F0 and cleaved F1 forms at a ratio of 34%:66%, as determined by 
densitometry.  In contrast, only faint bands representing the F0 precursor were 
seen for the double cleavage site mutants F117 and F130 in the absence of 
trypsin (Fig. 4.11, upper-left panel).  However, and in contrast to the results 
seen with transfected cells (Fig. 4.4B), prominent bands representing a partially- 
cleaved intermediate (F1+) were observed for both F117 and F130.  The 
partially-cleaved intermediate F1+ has previously been observed for F_RSV, 
and results from cleavage at site I in the absence of cleavage at site II 
(González-Reyes et al., 2001; Ruiz-Argüello et al., 2002).  The presence of F1+ 
was confirmed by the use of a polyclonal serum F_RSV_104-117 (Fig. 4.11, 
lower-left panel), which recognises amino acids 104-117 of F_RSV, (an epitope 
included in the intervening pep27 region between the two cleavage sites that is 
also present in the F117 and F130 mutant proteins).  The difference in migration 
between intermediate cleavage products for F117 and F130 may reflect 
differential glycosylation of pep27, since F117 contains 2 potential N-
glycosylation sites within pep27, whereas F130 possesses 3 potential sites (see 
Fig. 4.9A).  It has previously been estimated that at least two of the three sites 
are N-glycosylated for F_RSV pep27 (Zimmer et al, 2001a).  The absence of an 
F1+ intermediate cleavage product in transfected cells (Fig. 4.4B) may result 
from the different expression system used or the distinct antibody (MAb GB5) 
employed in Western blotting.   
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Interestingly, the proportion of fully-cleaved F1 protein was approximately the 
same for single cleavage site mutant Fc (66%) as double cleavage site mutants 
F117 (64%) and F130 (66%), suggesting that the insertion of a second, 
upstream cleavage site does not significantly affect cleavage of site II.  In the 
presence of trypsin, the F protein of all rSeV was completely cleaved to F1 (Fig. 
4.11, upper-right panel).  Completion of cleavage of F117 and F130 at both 
sites was additionally confirmed by loss of reactivity with the F_RSV_104-117 
serum (Fig. 4.11, lower-right panel).  Thus, both cleavage sites I and II are 
functional in double cleavage site mutants SeV-F117 and SeV-F130.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Proteolytic cleavage of rSeV.  Western blotting was employed to analyse the cell 
culture supernatant from infected LLC-MK2 cells (MOI 0.05) incubated for 96 h in the absence 
(left panel) or presence (right panel) of trypsin. Western blots were developed using polyclonal 
rabbit sera F_SeV_CT (upper panel), which recognises SeV F protein, or F_RSV_104-117 
(lower panel), which recognises amino acids 104-117 of the RSV F protein (pep27).  Also 
indicated are bands representing uncleaved F protein precursor (F0), the fully-cleaved F1 chain 
(F1) and the partially-cleaved intermediate (F1+), which results from cleavage at site I in the 
absence of cleavage at site II.  The percentage of F protein cleavage to F1 in the absence of 
trypsin (upper-left panel); (Fc 66%, F117 64%, F130 66%), was determined by densitometry.  
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4.4.5 Thermostability of recombinant Sendai virus 
 
Given the increased virus titres seen at 33°C (Table 4.1 ), it was hypothesised 
that double cleavage site mutants may have decreased thermostability.  
Recombinant Sendai viruses were purified from the allantoic fluid of 
embryonated eggs by sucrose gradient centrifugation and pre-incubated at 
37°C for 2, 4, or 6 h.  Heat-treated rSeV were subseq uently tested for their 
ability to mediate haemolysis of guinea pig erythrocytes.  Recombinant SeV 
were incubated at 33°C for 45 min with 0.5 ml guinea  pig erythrocytes (1% 
vol/vol), and the extent of haemolysis determined by measuring optical density 
at 520 nm.  Haemolysis results from changes in membrane permeability of 
erythrocytes following viral fusion, and can therefore be used as a measure of 
virus-cell fusion.  Haemolysis directed by wt SeV-FH was significantly more 
resistant to heat treatment than the cleavage site mutant viruses (Fig. 4.12A), 
retaining approximately 40% haemolytic activity even after 6 h of heat 
treatment, in agreement with previously published results for the fusion of SeV 
with liposomes (Wharton et al., 2000).  In contrast, all cleavage site mutants 
were more readily inactivated by heat treatment.  In particular, haemolysis 
directed by the double cleavage site mutant SeV-F130, which contains the 
complete pep27 region of F_RSV, was reduced to approximately 20% following 
just 4 h incubation at 37°C.  We subsequently tested th e ability of heat-treated 
virus obtained from cell culture supernatants to infect LLC-MK2 cells. As shown 
in Fig. 4.12B, the titre of heat-inactivated viruses reflects the haemolysis results, 
since wt SeV-FH was more resistant to heat treatment than the cleavage site 
mutants.  Following 6 h incubation at 37°C, the titre  of wt SeV_FH remained 
approximately 2 logarithms higher than the cleavage site mutant viruses, with 
SeV-F130 displaying the lowest titre following heat treatment.  Thus, insertion of 
one or both F_RSV cleavage sites in F_SeV leads to reduced thermostability, 
since cleavage site mutants display reduced haemolytic activity and replicate to 
lower titres than wt SeV-FH following heat treatment.  Moreover, the double 
cleavage site F130 mutant that contains the complete pep27 region, and thus 
most closely resembles F_RSV, was the least thermostable virus.   
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Figure 4.12. Thermostability of recombinant Sendai viruses. (A) Purified SeV was pre-
incubated at 37°C for 2, 4 or 6 hours, and subseque ntly incubated at 33°C for 45 min with 0.5 
ml washed guinea pig erythrocytes (1% vol/vol in PBS).  Haemolysis was measured by 
determining the optical density of the erythrocyte supernatant at 520 nm.  Results represent the 
mean of two independent experiments performed in duplicate. (B) Supernatant from infected 
LLC-MK2 cells was pre-incubated at 37°C for 2, 4 or  6 hours, and subsequently titrated on LLC-
MK2 cells in 96-well plates by immunohistochemical staining.  Results represent the mean of 
three independent experiments.  
 
4.5  Effect of fusion protein cleavage site mutations on cell-cell and 
virus-cell fusion by recombinant Sendai virus  
 
4.5.1  Formation of syncytia by recombinant Sendai virus mutants  
 
The ability of cleavage site mutant viruses to direct cell-cell fusion was 
compared by infection of LLC-MK2 cells grown in microchamber culture slides 
at an MOI of 0.5.  Infected cells were incubated in the absence or presence of 
trypsin at 37ºC for 30 h.  Fixed cells were subsequently stained with the 
monoclonal antibody GB5 that recognises F_SeV (Fig. 4.13A), and the extent of 
syncytia formation by rSeV was quantitated by counting the number of nuclei 
per syncytium (Fig. 4.13B).  The presence of trypsin was essential for the 
formation of syncytia by SeV-FH, whereas all rSeV cleavage mutants formed 
syncytia in the absence of trypsin.  As can be seen from Fig. 4.13, double 
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cleavage site mutant viruses formed larger syncytia than single cleavage site 
mutants.  In particular, double cleavage site mutants SeV-F117 and SeV-F130 
formed syncytia that were approximately four times the size of syncytia formed 
by wt SeV-FH in the presence of trypsin.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Syncytium formation assay.  (A) LLC-MK2 cells growing in microchamber wells 
were infected with SeV-FH, SeV-Fc, SeV-F117 or SeV-F130 viruses at an MOI of 0.5 in the 
absence or presence of trypsin.  Infected cells were processed for syncytia formation 30 h post-
infection.  (B) The number of nuclei in ten syncytia (chosen at random) in duplicate infections 
were counted using an AxioCam HRC digital camera (20x magnification).  Results are 
representative of three independent experiments. 
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4.5.2  Cell content mixing by recombinant Sendai virus mutants  
 
Further quantitation of cell-cell fusion by recombinant viruses was carried out by 
analysis of cell content mixing using the luciferase reporter gene assay.  BSR-
T7/5 cells were infected with rSeV (MOI 5), and subsequently mixed (14 h post-
infection) with LLC-MK2 cells, which had been previously transfected with a 
plasmid encoding the luciferase gene (pTM1-Luc).  The two populations of cells 
were left to fuse for 3 h at 37ºC (Fig. 4.14A) or 33ºC (Fig. 4.14B) in the absence 
or presence of trypsin.  Results are expressed as a percentage of wild-type 
fusion (fusion of SeV-FH in the presence of trypsin).  Cell-cell fusion mediated 
by the single cleavage site SeV-Fc mutant virus was not significantly increased 
with respect to wt SeV-FH at either 33ºC or 37ºC.  In contrast, double cleavage 
site mutants SeV-F117 and SeV-F130 displayed increased cell-cell fusion, 
particularly at 33ºC, with SeV-F117 producing the highest level of cell-cell fusion 
(approximately 3.5 times the level of wt cell fusion in the presence of trypsin at 
33ºC).  The increased titres seen for double cleavage site mutant viruses, 
particularly at 33ºC (Table 4.1) may reflect increased cell-cell spread (Figures 
4.13 and 4.14).  In summary, insertion of double F_RSV cleavage sites in 
F_SeV leads to an increase in both syncytia size and the extent of cell content 
mixing.   
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14. Quantitative cell-cell fusion assay.  BSR-T7/5 cells were infected with SeV-FH, 
SeV-Fc, SeV-F117 or SeV-F130 viruses at an MOI of 5 and incubated for 14 h in the absence 
or presence of trypsin.  LLC-MK2 cells, which had previously been transfected with pTM1-Luc, 
were overlayed onto infected BSR-T7/5 cells 14 h post infection, and incubated in the absence 
or presence of trypsin for 3 h at 37°C (A) or 33°C (B) to allow fusion.  Cells were subsequently 
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lysed and analysed for luciferase activity.  Results (relative light units) are expressed as a 
percentage of wild-type (wt) fusion (SeV-FH + trypsin), with mean values from at least two 
independent experiments shown.   
 
4.6  Dependence of recombinant Sendai viruses containing fusion 
protein cleavage site mutations on sialic acid for infection 
 
4.6.1  Effect of neuraminidase treatment on the infectivity of recombinant 
Sendai virus mutants  
 
Double cleavage site mutant F_SeV proteins were able to fuse transfected cells 
in the absence of co-expression of the HN attachment protein (Rawling et al., 
2008).  It was therefore of interest to examine the dependency of recombinant 
Sendai viruses containing mutations at the F protein cleavage site on the 
interaction between HN and sialic acid for infection.  LLC-MK2 cells grown in 
microchamber culture slides were treated with 120 mU neuraminidase (NA) for 
90 min at 37°C in order to eliminate cell surface sial ic acid receptors.  Cells 
were subsequently infected with rSeV at an MOI of 1, and incubated in the 
absence of trypsin.  The extent of infection was revealed by immunofluoresence 
of fixed cells with MAb GB5 at 20 h post-infection.  The level of infection in 
response to neuraminidase treatment was determined by counting the number 
of infected cells.  As shown in Fig 4.15A, both single cleavage site viruses SeV-
FH and SeV-Fc failed to produce significant infection in cells pre-treated with 
neuraminidase.  In contrast, double cleavage site mutant viruses SeV-F117 and 
SeV-F130 retained the ability to infect neuraminidase-treated cells, producing 
approximately 40% infection following neuraminidase treatment, compared to 
approximately 10% infection produced by single cleavage site mutants (Fig. 
4.15B).   
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Figure 4.15. Effect of neuraminidase treatment on rSeV infection.  (A) LLC-MK2 cells 
growing in microchamber wells were pre-treated with 120 mU neuraminidase (NA) for 90 min at 
37ºC, and subsequently infected with SeV-FH, SeV-Fc, SeV-F117 or SeV-F130 viruses at an 
MOI of 1.  Cells were processed for immunostaining 20 h post-infection.  (B) The number of 
infected cells in five fields (chosen at random) in duplicate infections were counted using an 
AxioCam HRC digital camera (20x magnification).  Also indicated is the percentage infection in 
NA-treated cells compared to untreated cells.  Results are representative of three independent 
experiments. 
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4.6.2  Comparison of the ability of recombinant Sendai virus mutants to 
infect cells devoid of sialic acid receptors 
 
To further examine the ability of double cleavage site mutants to infect cells 
devoid of sialic acid receptors, we infected a CHO cell line (Lec2), which is 
defective in sialic acid expression (Stanley et al., 1975).  Lec2 are a derivative 
of Pro-5 cells, and display a 90% reduction in the sialylation of glycoproteins 
due to defective transport of CMP-sialic acid into the trans-Golgi compartment 
(Deutscher et al., 1984; Stanley et al., 1980).  Lec2 and Pro-5 cells were 
infected in microchamber culture slides with an MOI of 1 and subjected to 
immunofluorescent staining at 20 h post infection with the GB5 MAb.  Whereas 
the single cleavage site viruses SeV-FH and SeV-Fc were unable to produce 
significant infection of Lec-2 cells, both double cleavage site viruses SeV-F117 
and SeV-F130 were able to infect Lec2 cells, albeit at a reduced level compared 
to the level of infection observed in Pro-5 cells (Fig. 4.16A).  Syncytia formation 
was not observed in Lec2 cells, which may reflect the lower level of infection by 
SeV-F117 and SeV-F130 in this cell type.   
 
In order to quantify the immunofluorescence results, an ELISA was carried out 
on infected Pro-5 and Lec2 cells at 20 h post infection, using the MAb GB5 
directed against SeV F protein (Fig. 4.16B).  Single cleavage mutants produced 
only a low level of infection in Lec2 cells (approximately 5% the level of infection 
of wt Pro-5 cells), which probably reflects the background level of sialic acid 
expression in Lec2 cells (Stanley et al., 1980).  However, double cleavage 
mutants SeV-F117 and SeV-F130 produced a higher level of infection in Lec2 
cells (26% and 28%, respectively).  Thus, while infection by double cleavage 
site mutants is enhanced by conditions that favour an interaction between HN 
and sialic acid, the presence of two cleavage sites results in a reduced 
dependency on the HN protein for infection. 
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Figure 4.16. Infection of sialic acid-deficient cells.  (A) Pro-5 or sialic acid-deficient Lec2 
cells growing in microchamber wells were infected with SeV-FH, SeV-Fc, SeV-F117 or SeV-
F130 viruses at an MOI of 1.  Cells were processed for immunostaining 20 h post-infection.  (B)  
Pro-5 or Lec2 cells growing in 96-well plates were infected with SeV-FH, SeV-Fc, SeV-F117 or 
SeV-F130 viruses at an MOI of 1 and fixed 20 h post infection.  Cells were subsequently stained 
for expression of SeV F protein with MAb GB5 and the optical density at 490 nm measured in 
order to quantitate infection.  The percentage infection in Lec2 cells relative to Pro-5 cells is 
indicated.  Results represent the mean of three independent experiments performed in 
duplicate.    
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5.  DISCUSSION 
 
5.1  Effect of cleavage site mutations on cell-cell fusion mediated by 
Sendai virus fusion protein 
 
RSV is unique among paramyxoviruses, since the RSV fusion protein (F_RSV) 
contains two (rather than one) multibasic cleavage sites, and is able to fuse with 
target cell membranes in the absence of a separate attachment protein.  On 
comparison of cell-cell fusion mediated by RSV and SeV fusion proteins, it was 
observed that co-expression of the G protein increased cell-cell fusion mediated 
by F_RSV by approximately two-fold in a quantitative assay (Fig. 4.2B).  
Therefore, while not a strict requirement, G enhances F_RSV-mediated cell-cell 
fusion by a mechanism that remains essentially unknown.  These results are in 
good agreement with those of Techaarpornkul et al., 2001, who reported a 
similar level of fusion enhancement by the G protein in recombinant RSV that 
expressed either F or both F and G proteins.  Human metapneumovirus 
(HMPV) F protein has also been shown to mediate cell-cell fusion (Schowalter 
et al., 2006) and virus-cell fusion (Biacchesi et al., 2004) in the absence of the 
attachment G protein, suggesting that members of the Pneumovirinae subfamily 
have evolved attachment protein-independent mechanisms of F protein 
activation.  In contrast, F_SeV displayed an absolute requirement for both HN 
co-expression and trypsin for cell-cell fusion, confirming previously published 
results (Scheid and Choppin 1974).   
 
F_SeV protein contains a single basic cleavage site (R116), whereas F_RSV
 
requires cleavage of two furin-dependent cleavage sites (RARR109 and 
KKRKRR136) for cell-cell fusion (González-Reyes et al., 2001; Zimmer et al., 
2001a).  As shown in Fig. 4.3, a number of chimeras between RSV and SeV 
fusion proteins were constructed in order to determine whether the differential 
requirements for fusion exhibited by F_RSV
 
and F_SeV are related to the 
distinct proteolytic processing pathways of the two proteins (Rawling et al., 
2008).   
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Insertion of the complete F_RSV cleavage site II (KKRKRR) in F_SeV to form 
the Fc mutant augmented cell-cell fusion in an HN-dependent manner, and 
decreased the dependence on trypsin for fusion (Fig. 4.5A).  The presence of 
six basic residues at the cleavage site of Fc also increased cleavage and cell-
cell fusion over the minimal furin recognition sequence present in F_RKR.  
However, the Fc mutant was still dependent on the co-expression of HN for cell-
cell fusion (Fig. 4.5B).  Double cleavage site mutants (F110, F117, F∆ and 
F130) were more susceptible to proteolytic processing by trypsin and formed 
larger syncytia than single cleavage site mutants (Figs. 4.4 and 4.5).  The 
presence of two cleavage sites may increase F protein proteolytic processing, 
thereby increasing the number of F protein molecules available for engagement 
in membrane fusion.  Moreover, all double cleavage site F_mutants also fused 
cells to form syncytia in the absence of the HN protein, thus mimicking the 
unique properties of F_RSV to fuse cells in the absence of attachment protein 
co-expression (Fig. 4.5B).   
 
The F117 double cleavage mutant formed the largest syncytia in the absence of 
HN co-expression.  However, in contrast to the syncytium formation assay, the 
level of HN-independent cell content mixing produced by F117 was lower than 
that of wild-type F_SeV co-expressed with the HN protein (Fig. 4.6).  Similarly, 
PIV5 F protein mutants (W3A strain) that were found to form syncytia in the 
absence of HN co-expression did not display cell-cell fusion activity in a 
quantitative content mixing assay (Horvath et al., 1992).  It was hypothesised 
that unstable PIV5 F proteins are able to fuse with neighbouring cells to form 
syncytia.  In contrast, the reporter gene assay involves the interaction between 
two distinct populations of cells, and may depend to a greater extent on the 
coordination of attachment and activation of F protein mutants for fusion.  Thus, 
the ability of double cleavage site mutant F_SeV proteins to reproduce the 
attachment protein-independent phenotype of F_RSV in both syncytium 
formation and cell content mixing assays suggests that the presence of two 
multibasic cleavage sites may represent an alternative strategy to regulate the 
activation of RSV F protein for cell-cell fusion in the absence of a separate 
attachment protein.     
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The intervening segment between the two cleavage sites modulated the 
capacity of the F_SeV protein to fuse membranes, and this modulation 
appeared greater in the absence of HN.  In particular, while the F117 mutant 
formed large syncytia without HN, the F∆ mutant produced only small syncytia 
(Fig. 4.5).  F∆ is related to F117 by a deletion N-terminal to the second 
cleavage site, which results in removal of an N-glycosylation motif that has 
previously been shown to be glycosylated in the Z strain of SeV F protein 
(Segawa et al., 2000).  There are three N-glycosylation sites present in pep27, 
and it has been estimated that at least two of the three sites are glycosylated 
(Zimmer et al., 2001a).  Mutation of one site (N126), resulted in increased 
F_RSV cell-cell fusion, suggesting that differential glycosylation of pep27 may 
modulate fusion (Zimmer et al., 2001b; Zimmer et al., 2002).  Similarly, it has 
been demonstrated that an oligosaccharide in the vicinity of the influenza virus 
HA cleavage site interferes with HA cleavage (Kawaoka and Webster 1989; 
Deshpande et al., 1987) and fusion (Ohuchi et al., 1997).  
 
5.2  Effect of fusion protein cleavage site mutations on the fusion and 
infectivity of recombinant Sendai virus  
 
The results from chimeric F_SeV mutant proteins indicated that the presence of 
two multibasic cleavage sites may represent a strategy to activate the RSV F 
protein for cell-cell fusion in the absence of an attachment protein (Rawling et 
al., 2008).  However, it has been suggested that cell-cell and virus-cell fusion 
processes have different structural requirements (Connolly and Lamb 2007).  It 
was therefore of interest to generate recombinant Sendai viruses (rSeV) that 
expressed mutant F proteins containing one or both F_RSV cleavage sites, 
separated either by a partial or complete intervening pep27 sequence (Fig. 
4.9A; Rawling et al., 2011).  Rescued rSeV were initially passaged in 
embryonated chicken eggs, as detailed in Fig. 4.9, in order to increase virus 
titre.  As indicated in the legend of Fig. 4.9, double cleavage site mutants SeV-
F117 and SeV-F130 were attained at lower titres following amplification in eggs 
than single cleavage site mutants SeV-FH and SeV-Fc.  However, it is not 
known if this reflects lower replication in eggs or lower efficiency of rescue of 
the double cleavage site viruses compared with single cleavage site viruses.  In 
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contrast, while the overall titres obtained in the presence of trypsin after 96 h 
were similar for all rSeV (Fig. 4.10), double cleavage site rSeV replicated with 
slightly faster replication kinetics during the first 48 h of replication, in particular 
at 33°C (Table 4.1).  Thus, it is possible that double cleavage site viruses 
display greater pathogenicity or stimulate the innate immune response to a 
greater extent than single cleavage site viruses in embryonated eggs.   
 
Similarly to the results seen in transfected cells, the presence of both F_RSV 
cleavage sites was found to increase the fusogenicity of rSeV, as measured by 
both syncytium formation and cell content mixing fusion assays (Figures 4.13 
and 4.14).  In addition, double cleavage site rSeV were able to infect cells 
devoid of sialic acid receptors (Figures 4.15 and 4.16), thereby mimicking the 
unique properties of RSV to fuse and infect cells in the absence of an 
attachment protein.  Cleavage site mutants, in particular the double cleavage 
site mutant F130, were also found to be less thermostable than wt SeV-FH (Fig. 
4.12).  It is likely that introduction of basic residues at the F_SeV cleavage site 
perturbs local protein conformation, thereby reducing thermostability.   
 
Previous studies have reported that mutations at the base of the prefusion head 
of PIV5 F protein (W3A strain), which result in hyperfusogenicity and HN-
independent syncytia formation (Horvath et al., 1992), act by destabilising the 
prefusion conformation of the F protein (Paterson et al., 2000; Russell et al., 
2003; Tsurudome et al., 2001).  Mutation of equivalent residues in the NDV F 
protein also resulted in hyperfusogenicity, the promotion of fusion at lower 
temperatures and cell-cell fusion in the absence of the HN protein, although 
cell-cell fusion required co-expression of the influenza HA attachment protein 
(Ayllón et al., 2010).  Such destabilising mutations may lower the activation 
energy required to trigger the F protein for fusion, thus reducing dependency on 
the HN protein for fusion (Connolly et al., 2009; Paterson et al., 2000).  
Similarly, the presence of double cleavage sites may reduce the thermostability 
of the F protein, thereby facilitating F activation for fusion by lowering the 
energy threshold required to trigger conformational changes involved in fusion.  
Indeed, our results indicated that the least thermostable mutant (SeV-F130) 
displayed the greatest ability to infect cells in an HN-independent manner.  
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However, there was no strict correlation between thermostability (Fig. 4.12) and 
HN-independence for infection, since the single cleavage site mutant SeV-Fc 
was less thermostable than the wild-type SeV-FH, but still required sialic acid 
receptors for infection (Figures 4.15 and 4.16). 
 
Destabilising mutations that resulted in increased cell-cell fusion of the murine 
leukaemia virus (MLV) env glycoprotein were previously shown to be 
disadvantageous for virus growth (Lavillette et al., 1998).  It was hypothesised 
that unstable env proteins at the cell membrane are continuously replaced by 
new molecules, which are able to mediate cell-cell fusion.  In contrast, such 
unstable proteins may be prematurely activated in the virus particle before 
virus-cell contact takes place, thereby inactivating the virus.  In contrast, 
hyperfusogenic double cleavage site mutant rSeV were able to infect cells 
devoid of sialic acid receptors, thereby reproducing the ability of RSV 
expressing the F protein in the absence of other cell surface glycoproteins to 
fuse and infect cells (Karron et al., 1997; Techaarpornkul et al., 2001; 2002).   
 
It is currently unknown how activation of the mutant F_SeV proteins for fusion 
could be co-oordinated with attachment of rSeV to target cells in the absence of 
sialic acid receptors.  It is possible that residual binding of HN to NA-treated 
LLC-MK2 cells (Fig. 4.15) or Lec2 cells (Fig. 4.16) is sufficient for fusion and 
entry of the less thermostable, double cleavage site mutant rSeV, whereas a 
higher level of attachment is required for fusion of the more thermostable SeV-
FH.  Alternatively, the double cleavage site viruses may bind to alternative 
receptors on the target cells.  F_SeV has previously been shown to mediate 
fusion of virosomes with red blood cells in the absence of the HN protein via an 
interaction with the asialoglycoprotein receptor (Bagai et al., 1993).  In addition, 
virus-like particles that expressed F_SeV protein in the absence of HN protein 
expression were able to infect cells via the asialoglycoprotein pathway (Leyrer 
et al., 1998), suggesting that the acquired ability of F_SeV to bind to cells 
permits activation of F_SeV for fusion in the absence of HN co-expression. 
   
The ability of recombinant RSV that lacks the attachment G protein to infect 
cells suggests that the RSV F protein alone is capable of binding to target cells 
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in order to mediate fusion.  It has been shown that F_RSV binds to cell surface 
glycosaminoglycans (GAGs), although less efficiently than the attachment G 
glycoprotein (Feldman et al., 2000; Karger et al., 2001; Techaarpornkul et al., 
2002).  Indeed, infection by recombinant RSV is enhanced approximately three-
fold by the presence of the G protein (Schlender et al., 2003; Techaarpornkul et 
al., 2001).  Similarly, infection by the double cleavage site rSeV mutants was 
enhanced by the presence of sialic acid receptors on target cells (Figures 4.15 
and 4.16).   While the precise region of the F protein involved in the interaction 
with GAGs has not been mapped, a heparin-binding peptide corresponding to 
F_RSV cleavage site II and part of the fusion peptide 
(131_KKRKRRFLGFLLGVGSA_147) was able to inhibit both attachment and 
infection by RSV (Crim et al., 2007), suggesting that the cleavage site II region 
of F_RSV interacts with cell surface GAGs.    
 
The furin-dependent cleavage site of a number of other viruses has also been 
suggested as a candidate heparan sulfate binding domain (de Haan et al., 
2008; Klimstra et al., 1999; Pasquato et al., 2007).  Binding of Sindbis virus E2 
protein to heparan sulphate correlates with the amount of uncleaved E2 present 
in the virion (Klimstra et al., 1999).  Interestingly, the HIV-1 gp160 protein also 
contains two furin cleavage sites, which are separated by 8 amino acids 
(KAKR503 and REKR511).  While cleavage site REKR503 is inefficiently 
cleaved, studies using synthetic peptides indicate that binding of the uncleaved 
REKR503 site to heparin induces conformational changes that expose site 
KAKR511 for furin cleavage (Pasquato et al., 2007).  The presence of partially-
cleaved F protein from rSeV grown in the absence of trypsin indicates that the 
uncleaved, multibasic cleavage site II is present on approximately one third of F 
molecules (Fig. 4.11), and would thus be available to bind to cell surface GAGs.  
Binding of cleavage site II to GAGs may promote fusion in the absence of a 
separate attachment protein by facilitating either completion of cleavage of all F 
molecules within the trimer by furin present at the plasma membrane (Thomas 
2002), or the fusion of adjacent, F protein trimers that are already fully-cleaved.   
 
However, only double cleavage site rSeV mutants were able to infect sialic acid-
deficient cells, suggesting that furin cleavage site I is also involved in the 
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binding to GAGs and/or the triggering of fusion.  An attractive hypothesis is that 
the insertion of F_RSV cleavage site I directly mediates attachment to cells.  
However, a linear peptide corresponding to cleavage site I did not bind to 
heparin-agarose beads (Crim et al., 2007).  Alternatively, insertion of cleavage 
site I may alter the local structure of the F_SeV proteolytic processing region, 
thereby facilitating the projection of cleavage site II from the surface of the F 
prefusion structure to bind to target cell GAGs.  This hypothesis is supported by 
previous findings, which suggest that the sequence surrounding the F_SeV 
cleavage site is important for fusion (Heminway et al., 1995).  While the 
conformation adopted by the pep27 region in the prefusion F protein is not 
known, it is likely to form a glycosylated, surface-exposed loop between the two 
cleavage sites, which are accessible to exogenous trypsin (Fig. 1.4B).  We are 
currently conducting further experiments to test the binding of cleavage site II to 
cell surface GAGs (Trento et al., unpublished data).   
 
5.3  Fusion and infection of RSV F protein cleavage site mutants 
 
Interactions between RSV and GAGs may be important in natural infection, 
since heparin has been shown to inhibit the initial tissue culture passage of 
primary isolates (Teng et al., 2001).  However, recombinant RSV expressing the 
F protein as the only surface glycoprotein was able to produce a low level of 
infection (25%) in cells devoid of GAGs, suggesting that F_RSV also binds to 
alternative receptor(s), which have yet to be identified (Techaarpornkul et al., 
2002).  Studies using chimeric RSV, in which the human RSV (HRSV) F2 
subunit was replaced by the bovine RSV (BRSV) F2, have shown that F2 
determines the species-specificity of infection of primary haematopoietic cells. 
In contrast, RSV G may bind to GAGs in a non-specific manner in order to 
facilitate access of F2 to specific receptors (Schlender et al., 2003).   
 
BRSV F protein is also characterised by double cleavage sites (RAR/KR109 
and KKRKRR136), which are separated by an intervening sequence that has 
the same length as that of HRSV (27 amino acids; pep27), but which lacks 
sequence identity with human pep27 (Fig. 5.1).  Following double cleavage and 
release of the intervening peptide, it has been suggested that subsequent post-
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translational modifications convert BRSV pep27 into a biologically active, 
tachykinin-like peptide (virokinin), which modulates the host immune response 
(Valarcher et al., 2006; Zimmer et al., 2003).  However, no such role has been 
attributed to HRSV pep27, since the HRSV pep27 sequence possesses neither 
the tachykinin motif (Fig. 5.1) or tachykinin-like activity (Zimmer et al., 2003).   
 
 
 
 
 
 
 
 
 
 
Fig. 5.1. Sequence alignment of BRSV and HRSV pep27.  The amino acid sequences of 
bovine (BRSV, strain ATue51908) and human (HRSV, Long strain) respiratory syncytial virus 
pep27 regions were aligned using the BioEdit Sequence Alignment Editor version 7.0.9.0 (Hall 
1999).  Amino acids are coloured according to identity and shaded for similarity.  The 
tachykinin-like sequence (FYGLM) found in BRSV is indicated (Zimmer et al., 2003).   
 
Mutations of F_RSV cleavage site I in the context of recombinant BRSV 
(rBRSV) reduced both the replication rate of rBRSV in cell culture and the size 
of syncytia (Zimmer et al., 2002).  It was suggested that glycosylated pep27 that 
remains attached to F2 in the absence of cleavage at site I interferes with 
conformational changes required for fusion, thus reducing the ability of site I 
rBRSV mutants to replicate.  Accordingly, replication of pep27 deletion mutants 
(∆106-130; Zimmer et al., 2002 or ∆109-136; König et al., 2004) was not 
significantly affected with respect to wt rBRSV.  In contrast, syncytia formation 
was drastically affected, suggesting that virus-cell and cell-cell fusion processes 
have different requirements with respect to double cleavage (Zimmer et al., 
2002).  We also found that mutation of F_RSV by deletion of pep27, producing 
F_∆108-120 and F_∆108-132 mutants (Fig. 4.7A), led to an increase in cell-cell 
fusion activity compared to F_R108/109N (Fig. 4.7C).  However, fusion of cells 
transfected with F_RSV cleavage site mutants was reduced with respect to wt 
HRSV_pep27
BRSV_pep27
FYGLM
Tachykinin-like sequence
RARRELPRFMNYTLNNTKKTNVTLSKKRKRR
RAKRGIPELIHYTRNSTKKFYGLMGKKRKRR
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F_RSV, even in the presence of RSV G co-expression.  Since co-expression of 
the attachment G protein with the F_RSV cleavage site mutants failed to fully 
restore wild-type levels of fusion, it appears that cleavage site mutation directly 
interferes with fusion of F_RSV, rather than simply reducing the binding of 
F_RSV to cells.  Given the potential role of double cleavage in attachment 
protein-independent fusion, it would be of interest to investigate the phenotype 
of F_RSV cleavage site mutations in the context of a recombinant RSV lacking 
the attachment G protein.   
 
Zimmer et al., (2005) have previously rescued rSeV in which both SeV F and 
HN proteins were replaced by a modified RSV F protein, consisting of the RSV 
F protein ectodomain fused to the SeV F protein transmembrane and 
cytoplasmic domains.  Replication of rSeV expressing chimeric F_RSV was 
independent of trypsin and sialic acid, although rSeV co-expressing HN and 
chimeric F_RSV produced significantly higher titres.  The authors concluded 
that the HN protein performed an accessory function in the chimeric viruses 
similar to that of the RSV G protein, which enhances RSV attachment and 
infection, but which is dispensable for virus replication (Schlender et al., 2003; 
Techaarpornkul et al., 2001).  Furthermore, Schlender et al., (2003) have shown 
that the RSV F2 region is responsible for species-specific infection of primary 
cells, which is enhanced in a non-specific manner by the G attachment protein.  
These results reflect the behaviour of rSeV double cleavage site mutants (SeV-
F117 and SeV-F130), which although capable of sialic acid-independent 
infection, displayed enhanced infection of cells expressing sialic acid receptors 
for the HN attachment protein (Fig. 4.16).  Interestingly, the F2 region employed 
by Schlender et al., (amino acids 1-136) included the double cleavage sites and 
pep27 region that conferred HN-independent infection properties on rSeV 
(Rawling et al., 2011).  Thus, it is possible that binding of the RSV F2 pep27 
region to cells determines the species-specificity of RSV infection.  While other 
regions of F_RSV could also contribute to attachment protein-independent 
fusion, the results presented in this thesis indicate that the double cleavage 
region of F_RSV may play a crucial role in the unique ability of RSV to fuse and 
infect cells in the absence of a separate attachment protein.   
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The correct timing of F activation (triggering) is essential for paramyxovirus 
entry.  Activation of the F protein must only occur in proximity to the target cell 
membrane to prevent premature inactivation of virus particles.  For the 
Paramyxovirinae subfamily it remains to be determined how, following 
attachment to target cell sialic acid receptors, potential conformational changes 
in the HN protein co-ordinate subsequent activation of the F protein for fusion.  
Moreover, it is currently unknown how fusion is triggered for members of the 
Pneumovirinae subfamily, which do no depend on a separate attachment 
protein for fusion and infection.  Interestingly, syncytia formation by the human 
metapneumovirus F protein expressed alone in transfected cells was dependent 
on low pH (Schowalter et al., 2006), at least for certain strains (Herfst et al., 
2008).  It is therefore possible that members of the Pneumovirinae subfamily 
have evolved distinct mechanisms of F protein activation compared to those of 
the Paramyxovirinae subfamily.   
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6.   CONCLUSIONS  
 
1. Chimeric F_SeV mutants containing one or both F_RSV cleavage sites, 
separated either by a partial or complete intervening pep27 sequence, 
were expressed at a similar level to wild-type (wt) F_SeV on the surface 
of transfected cells. 
2. F_SeV mutants with double cleavage sites were more susceptible to 
proteolytic processing in the presence of trypsin. 
3. Double cleavage site F_SeV mutants fused transfected cells to a greater 
extent than single cleavage site mutants, both in the absence or 
presence of trypsin. 
4. Insertion of both F_RSV cleavage sites in F_SeV reduced dependency 
on the HN attachment protein for syncytia formation.  
5. Recombinant SeV (rSeV) expressing cleavage site mutant F_SeV 
proteins were rescued to high titres following amplification in 
embryonated eggs. 
6. Double cleavage site mutant rSeV replicated with slightly faster 
replication kinetics than single cleavage site rSeV, in particular at 33ºC. 
7. All rSeV expressing F proteins with furin-dependent cleavage sites were 
less thermostable than wt rSeV. 
8. Double cleavage site rSeV mutants fused infected cells to a greater 
extent that single cleavage site mutants, in particular at reduced 
temperatures. 
9. rSeV containing two cleavage sites were able to fuse and infect cells 
lacking sialic acid receptors for the HN attachment protein.  Thus, 
infection by double cleavage site rSeV mutants is less dependent on the 
attachment protein. 
10. Insertion of both F_RSV cleavage sites in F_SeV in the context of rSeV 
mimics the unique cell-cell fusion and infection properties of RSV. 
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 CONCLUSIONES 
 
1. Los mutantes quiméricos de F_SeV que contienen uno o ambos sitios de 
corte de F_RSV, separados por una secuencia del pep27 parcial o 
completa, se expresaron en la superficie de células transfectadas a unos 
niveles equivalentes a aquellos de F_SeV wild-type. 
2. Los mutantes de F_SeV con doble sitio de corte fueron más susceptibles 
al procesamiento proteolítico en presencia de tripsina. 
3. Los mutantes de F_SeV con doble sitio de corte exhibieron una mayor 
capacidad de fusionar células transfectadas, ambos en ausencia o 
presencia de tripsina. 
4. La inserción de los dos sitios de corte de F_RSV en F_SeV reduzcó la 
dependencia de F de la proteína de unión al receptor (HN) para la 
formación de sincitios. 
5. Virus recombinantes Sendai (rSeV) que expresan distintas proteínas F 
con mutaciones del sitio de corte fueron rescatados en títulos elevados 
tras su amplificación en huevos embrionados. 
6. Los mutantes de rSeV con doble sitio de procesamiento exhibieron una 
cinética de replicación ligeramente más rápida que los mutantes con un 
único sitio de corte, particularmente a 33ºC. 
7. Todos los rSeV que expresan las distintas proteínas F con mutaciones 
del sitio de corte por furina manifestaron menor termoestabilidad que 
rSeV wild-type. 
8. Los mutantes rSeV con doble sitio de corte mostraron una mayor 
capacidad de fusionar células infectadas, particularmente a bajas 
temperaturas.  
9. Los virus rSeV con dos sitios de corte fueron capaces de fusionar e 
infectar células que carecen de receptores de ácido siálico para la 
proteína de unión HN.  Así, la infección por rSeV que tienen el doble sitio 
de corte es menos dependiente de la proteína de unión al receptor. 
10. La inserción de los dos sitios de corte de F_RSV en F_SeV en el 
contexto de rSeV se asemejan a las propiedades de fusión célula-célula 
y de infección de RSV. 
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8.  APPENDIX 
 
8.1  INTRODUCCIÓN 
 
8.1.1  Clasificación de paramixovirus 
 
La familia Paramyxoviridae consiste en una serie de virus envueltos, con un 
genoma compuesto por una hebra de RNA de polaridad negativa 
(Mononegavirales) e incluye virus humanos de gran prevalencia (sarampión, 
virus respiratorio sincitial), virus animales de gran importancia económica (virus 
de la enfermedad de Newcastle, virus de la peste bovina), así como los 
recientemente identificados virus letales Hendra y Nipah.  Los paramixovirus se 
subdividen en dos subfamilias: Paramyxovirinae y Pneumovirinae (Collins y 
Crowe 2007).  Los Paramyxovirinae y Pneumovirinae se distinguen 
morfológicamente por las diferencias en el tamaño y la forma de sus 
nucleocápsidas (Bhella y col., 2002), por el número de proteínas que codifican, 
y por las características de sus proteínas de unión al receptor (Figura 1.1). 
 
El virus Sendai (SeV) y el virus respiratorio sincitial (RSV) son miembros 
representativos de las subfamilias Paramyxovirinae y Pneumovirinae 
respectivamente.  RSV se aisló en 1956 de un chimpancé de laboratorio con 
resfriado común (Blount y col., 1956).  Un año más tarde, RSV fue aislado a 
partir de dos niños con enfermedades respiratorias, y se confirmó mediante 
estudios serológicos que la infección era común en niños (Chanock y col., 
1957).  RSV es actualmente reconocido como la causa más importante de 
enfermedades infantiles graves del tracto respiratorio en el mundo entero (Nair 
y col., 2010), y puede también provocar enfermedades serias en ancianos y 
enfermos inmunodeprimidos (Falsey y col., 2005).  RSV es considerado un 
patógeno de interés para el desarrollo de vacunas, sin embargo, la vacunación 
de recién nacidos con RSV inactivado con formalina (FI-RSV) en los años 60 
no produjo protección.  Más aún, la vacunación con FI-RSV se asoció con un 
aumento en la gravedad de la enfermedad en posteriores infecciones naturales 
con RSV (Openshaw y col., 2001).  Por otro lado, la infección natural con RSV 
no produce protección inmunológica duradera, y las infecciones repetidas a lo 
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largo de la vida son comunes.  Por tanto, los avances en el conocimiento de la 
biología de RSV son esenciales para el desarrollo de vacunas y agentes 
antivirales eficaces. 
 
El virus Sendai, también conocido como virus de la parainfluenza murina tipo I, 
es el responsable de infecciones muy contagiosas del tracto respiratorio en 
ratones, hamsters y ratas.  Este virus se estudia frecuentemente como modelo 
representativo de la familia Paramyxoviridae, con el fin de estudiar las 
características moleculares y propiedades biológicas de los paramixovirus 
(Faisca y Desmecht 2007).  El interés del estudio de SeV ha aumentado en 
años recientes debido a su potencial como vector de transferencia génica 
(Kinoh y Inoue 2008). 
 
8.1.2  Biología molecular de los paramixovirus 
 
8.1.2.1  Genoma y proteínas de los paramixovirus 
 
El genoma de los paramixovirus está formado por una cadena sencilla de RNA 
no segmentada de una longitud entre 15 y 19 kB.  Contiene dos regiones 
extracistrónicas, una en el extremo 3’ de aproximadamente 50 nucleótidos 
(leader), y otra región en el extremo 5’ de 50-161 nucleótidos (trailer), que son 
esenciales para la transcripción y la replicación.  También hay secuencias de 
control de la transcripción en las regiones anteriores y posteriores a cada gen, 
que están separados por regiones intergénicas.  Las regiones intergénicas de 
los Respirovirus son exactamente 3 nucleótidos, pero su longitud varía en los 
Pneumovirus entre 1-56 nucleótidos.  Los genomas de los paramixovirus 
contienen generalmente 5-10 genes unidos secuencialmente (Fig. 1.1), sin 
embargo, la capacidad de codificación puede ser amplificada mediante el uso 
de fases de lectura abierta o open reading frames (ORFs) solapantes. 
 
Proteínas de la nucleocápsida N, P, L y M2-1: Los paramixovirus están 
formados por una nucleocápsida estable central que está rodeada por una 
envuelta lipídica, que se incorpora a la partícula según el virus emerge de la 
célula huésped (Fig. 1.2).  La nucleoproteína (N) se une al RNA genómico 
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(polaridad -) y antigenómico (polaridad +) para formar el molde de la 
nucleocápsida helicoidal, que es la forma biológicamente activa del RNA viral 
(vRNA).  La estructura cristalina de un complejo de la proteína N de RSV reveló 
que la proteína es capaz de formar anillos decaméricos que se unen al RNA a 
través de una hendidura o groove formada por residuos básicos (Tawar y col., 
2009).  Por otro lado, N se une también a la fosfoproteína (P) y a la polimerasa 
(L) para formar el complejo ribonucleoproteína (RNP), que representa la unidad 
mínima de replicación (Grosfeld y col., 1995; Yu y col., 1995).  La proteína L es 
una RNA polimerasa viral dependiente de RNA (vRNAP), que se encarga de la 
transcripción del mRNA viral funcional, incluyendo el capping y la metilación del 
extremo 5’ y la poliadenilación del extremo 3’ (Ogino y col., 2005).  La proteína 
L se encuentra en muy pequeña concentración en las células infectadas.  Por 
ejemplo, cada nucleocápsida del virus Sendai está compuesta de 
aproximadamente 2600 moléculas de N, 300 de P y 50 de L (Lamb y col., 
1976).  Mientras que la proteína L posee toda la actividad catalítica del vRNAP, 
L se une al molde de la nucleocápsida por medio de la proteína P (Horikami y 
col., 1992).  La proteína P está fosforilada en residuos de Ser/Thr, y es un 
cofactor esencial para el funcionamiento de las proteínas L y N.  Finalmente, la 
proteína M2-1 (específica de los neumovirus), se incorpora también a la 
nucleocápsida.  Se transcribe desde el primer ORF del gen M2 y actúa como 
un factor esencial para facilitar la transcripción (Collins y col., 1995). 
 
Proteína matriz M: Como muestra la Figura 1.2, la proteína matriz (M) recubre 
la cara interna de la envuelta.  La proteína M es la más abundante en el virión y 
se cree que juega un papel central en la mofogénesis viral, mediante las 
interacciones con la cola citoplasmática de las glicoproteínas de la envuelta, la 
bicapa lipídica y la nucleocápsida.  La capacidad de la proteína M de 
autoasociarse, combinada con la interacción que se produce con la 
nucleocápsida, puede ser responsable de la escisión por gemación de los 
viriones (Ghildyal y col., 2006). 
 
Glicoproteínas de la envuelta HN/H/G, F y SH: Los paramixovirus contienen 
dos glicoproteínas integrales de membrana dentro de la envuelta lipídica, 
codificadas por el genoma viral: la proteína de fusión (F) y la de unión al 
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receptor (glicoproteína [G], hemaglutinina [H], o hemaglutinina-neuraminidasa 
[HN]), que forman espículas de 8-12 nm de la superficie del virion (Fig. 1.2).  
Todos los paramixovirus poseen una proteína de fusión, que facilita la fusión de 
las membranas celular y viral durante la entrada del virus.  Sin embargo, las 
características de la proteína de unión, que es la responsable de la unión del 
virus a la superficie de la célula diana, varían considerablemente entre las dos 
subfamilias de los Paramyxoviridae.  Las glicoproteínas de fusión y unión al 
receptor de los paramixovirus representan importantes dianas antigénicas, ya 
que inducen la producción de anticuerpos neutralizantes (Walsh y col., 1987).  
Dado que el interés de esta tesis se centra en la entrada de los paramixovirus 
en la célula, las proteínas de fusión y de unión serán descritas en detalle en la 
sección 1.3.   
 
El virus de las paperas, RSV y PIV5 poseen una tercera proteína de membrana 
de función desconocida: la proteína hidrofóbica pequeña (SH).  La proteína SH 
no es imprescindible para la replicación del virus RSV en cultivos celulares, 
aunque su delección de un RSV recombinante resultó en la atenuación del 
crecimiento viral (Bukreyev y col., 1997).  Las proteínas SH de los 
paramyxovirus inhiben la señalación TNF-α y la apoptosis de células 
infectadas, lo que podría favorecer la infección (Fuentes y col., 2007; Wilson y 
col., 2006).  Un análisis por microscopía electrónica de la proteína SH de RSV 
reveló unas estructuras en forma de anillo pentamérico o hexamérico con un 
poro central, que permitiría el paso de iones y moléculas pequeñas (Carter y 
col., 2010).  
 
Proteínas accesorias: El gen P/V/C de los paramixovirus dirige la expresión 
de una serie de proteínas accesorias (V, W, C’, C, Y1 y Y2 para SeV) mediante 
la edición del RNA y el uso de codones de traducción alternativos.  Aunque las 
proteínas accesorias no son esenciales para la infección, ejercen diversas 
funciones en el ciclo de crecimiento viral, incluyendo el control de la síntesis de 
RNA y la inhibición de los componentes celulares de la respuesta de interferon 
de tipo I (Goodbourn y Randall 2009).  Los neumovirus son únicos dentro de la 
familia Paramixovirinae, ya que no producen proteínas alternativas del gen de 
la P.  Sin embargo, RSV tiene dos genes adicionales que codifican dos 
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proteínas no estructurales (NS1 y NS2), que son capaces de inhibir la indución 
de interferon de tipo I en respuesta a las infecciones virales (Spann y col., 
2004).  Estas proteínas promueven el crecimiento de RSV, pero no son 
esenciales para su replicación in vivo (Teng y col., 1999; 2000).   
 
8.1.2.2  Ciclo Replicativo 
 
El ciclo replicativo completo de los Paramyxoviridae tiene lugar en el citoplasma 
de la célula diana (Fig.1.3).  La entrada viral requiere primero la unión de los 
viriones a la superficie celular.  Para los miembros de los géneros Rubulavirus 
y Respirovirus, los receptores celulares son moléculas que contienen ácido 
siálico.  Para la proteína de unión al receptor (HN) del virus Sendai, los 
receptores son gangliósidos que contienen ácido siálico (Markwell y col., 1980, 
1984).  En la mayoría de los neumovirus el receptor es desconocido, sin 
embargo, RSV interacciona con los glicosaminoglicanos de la superficie celular, 
en particular con heparán sulfato (Escribano-Romero y col., 2004; Feldman y 
col., 1999, 2000; Hallak y col., 2000; Karger y col., 2001).  Tras la unión, la 
proteína de fusión (F) de los paramixovirus induce la fusión de la envuelta viral 
con la membrana plasmática celular a pH neutro.   
 
La fusión de las membranas viral y celular permite la entrada de la 
nucleocápsida en el citoplasma, donde tiene lugar la transcripción del genoma 
viral por la vRNAP, dando lugar a un conjunto de mRNAs que son traducidos 
por los ribosomas celulares.  La vRNAP transcribe el molde genómico de 
polaridad negativa de manera secuencial a partir de un único promotor en el 
extremo 3’ del RNA para generar mRNAs poliadenilados y con estructura de 
cap. La transcripción se inicia en la señal de comienzo del primer gen (GS o 
gene start) en el extremo 3’ y procede a lo largo del genoma molde hasta que 
se alcanza la secuencia de final del gen (GE o gene end). El vRNAP escanea 
posteriormente las regiones intragénicas sin disociarse del genoma modelo, 
reiniciando la transcripción en el siguiente GS mediante un mecanismo start-
stop de transcripción. Esto da como resultado un gradiente polar 3’-5’ de 
mRNA, debido a que la probabilidad de que la polimerasa inicie la transcripción 
en los subsiguientes GS va disminuyendo según alcanza nuevas regiones 
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intragénicas.  Tras la traducción de los tránscritos primarios y la acumulación 
de proteínas virales, el genoma viral se replica para producir un antigenoma 
completo de polaridad positiva (cRNA).  El antigenoma representa una 
molécula intermedia en la replicación genómica, acomplejándose con la 
proteína N y actuando como molde para la posterior síntesis de genomas 
progenie.  La replicación eficiente del RNA de SeV depende de la llamada 
“regla del seis”, que consiste en que la longitud del genoma viral debe ser 
múltiplo de seis para replicarse de forma eficiente (Calain y Roux 1993).  Por el 
contrario, la replicación del genoma de RSV no sigue la regla del seis (Samal y 
Collins 1996).  De forma similar a otros virus con envuelta, los paramixovirus 
emergen de la membrana plasmática de la célula infectada en los sitios donde 
los componentes virales se han ensamblado.  Finalmente, las gemas se 
escinden, resultando en la liberación de las nuevas partículas virales. 
 
8.1.3  Glicoproteínas de la envuelta de los paramixovirus  
 
8.1.3.1  La proteína de fusión 
 
Las proteínas de fusión de los paramixovirus son las responsables de la 
entrada del virus, promoviendo la fusión entre la envuelta viral y la membrana 
plasmática celular a un pH neutro.  Además, las proteínas F que se expresan 
en la membrana plasmática de las células infectadas pueden dar lugar a la 
fusión entre células vecinas para formar sincitios multinucleados.  A pesar de la 
escasa identidad de secuencia entre ellas, las proteínas F de los paramixovirus 
comparten muchos elementos estructurales, incluyendo la localización de 
residuos cisteínas, glicinas y prolinas, lo que sugiere una estructura similar para 
todas.  En la Figura 1.4A se muestra como la proteína F tiene tres regiones 
hidrofóbicas principales: un péptido señal (SP) N-terminal que dirige la proteína 
al retículo endoplásmico durante su biosíntesis, una región transmembranal 
(TM) en la región C-terminal y un péptido de fusión (FP) situado en el extremo 
N-terminal de la cadena F1.  El péptido de fusión se inserta en la membrana de 
la célula diana durante el proceso de fusión de membranas (Russell y col., 
2001).  La proteína F de los paramixovirus contiene dos regiones con 
secuencias heptádicas (4-3) repetidas, HRA y HRB, situadas adyacentes al 
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péptido de fusión y al dominio transmembranal respectivamente.  Estas 
regiones tienen un papel crucial en el mecanismo de fusión de membranas (ver 
sección 1.3.3). 
 
La proteína F de los paramixovirus es un homotrímero (Russell y col., 1994) 
que pertenece a la clase I de la familia de proteínas virales de fusión, que 
comprende entre otras la proteína hemaglutinina (HA) del virus de la influenza, 
la proteína de la envuelta  gp160 del virus HIV, y la proteína G del virus Ébola.  
La fusión de membranas tiene lugar por medio del replegamiento de una forma 
prefusión metaestable de la proteína F (Figura 1.4B) a una forma posfusión 
más estable (Figura 1.4C), pasando por una serie de cambios 
conformacionales (revisión en Lamb y Jardetzky 2007).  Dichos cambios 
conformacionales resultan en la disposición de las regiones heptádicas de la 
proteína F (HRA y HRB) en un haz de 6 hélices o 6-helix bundle (6HB), que es 
característico de la estructura de postfusión (Figura 1.4C).  La estructura 6HB 
forma una superhélice (coiled-coil), que contiene un núcleo interno de tres 
hélices HRA rodeadas por tres hélices HRB antiparalelas (Baker y col., 1999; 
Zhao y col., 2000).  Esta disposición obliga a situarse al péptido de fusión y al 
dominio transmembranal en el mismo extremo de la proteína, y se cree que 
esto está relacionado directamente con la fusión de las membranas viral y 
celular, dado que la energía libre que se desprende en la formación del 6HB 
puede utilizarse para la fusión de las membranas (Melikyan y col., 2000; 
Russell y col., 2001). 
 
La proteína F se sintetiza como un precursor inactivo (F0), que requiere un 
procesamiento proteolítico que da lugar a dos cadenas polipeptídicas (F1 y F2), 
unidas por puentes disulfuro (revisión en Lamb y Jardetzky 2007).  El corte 
proteolítico es un requerimiento imprescindible para la activación de la proteína 
F.  El procesamiento proteolítico tiene lugar en un sitio mono- o multibásico que 
se encuentra adyacente al péptido de fusión, y es reconocido respectivamente 
por proteasas del tipo tripsina o tipo furina.  Las características del sitio de corte 
son claves para la patogenicidad viral, ya que se ha demostrado que la 
adquisición de un sitio de corte multibásico está relacionado con mayor 
patogenicidad e infección sistémica (Klenk y Garten 1994; Nagai y Klenk 1977).   
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La Tabla 1.1 muestra una comparación de secuencias de los sitios de corte de 
proteínas F representativas de los paramixovirus.  La proteasa intracelular 
furina, de la familia de las subtilisinas, es la responsable del procesamiento de 
proteínas con sitios multibásicos, incluyendo la F de RSV (F_RSV).  Por el 
contrario, la proteína F del virus Sendai (F_SeV) contiene un único aminoácido 
básico en el sito de corte (R116), y requiere la adición de tripsina a los cultivos 
celulares para que puedan tener lugar sucesivas rondas de replicación (Scheid 
y Choppin 1974; Kido y col., 1999).  Se cree que la proteasa triptasa Clara, que 
se secreta de las células Clara del epitelio bronquial, es la responsable de la 
activación de las proteínas con sitios de corte monobásicos en el tracto 
respiratorio del huésped murino (Kido y col., 1997; 1999). 
 
F_RSV
 
es único entre los Paramyxoviridae, ya que F_RSV contiene dos sitios 
de corte por furina (sito I, RARR109 y sitio II, KKRKRR136), que están 
separados por una región de 27 aminoácidos (pep27).  Los dos sitios de corte y 
la longitud de pep27 (pero no su secuencia) están altamente conservados en 
todas las cepas de RSV bovinas y humanas.  El procesamiento proteolítico en 
los dos sitios es necesario para que F_RSV
 
forme sincitios en células 
transfectadas (González-Reyes y col., 2001; Zimmer y col 2001a).  Mientras 
que la F_RSV
 
no necesita la co-expresión de la proteína de unión para la fusión 
de membranas (ver sección 8.1.3.4), se requiere el doble procesamiento y la 
liberación de pep27, que se secreta al medio (Ruiz-Argűello y col., 2002).  La 
existencia de dos sitios proteolíticos en F-RSV es única entre los 
paramixovirus, aunque se han observado dos sitios de corte en la proteína 
“spike” (S) del coronavirus SARS (Belouzard y col., 2009). 
 
No se conoce en profundidad la función del doble procesamiento y de la 
liberación de pep27, pero se sabe que el procesamiento está asociado con un 
cambio de forma de la proteína F_RSV
 
(Melero 2007; Ruiz-Argűello y col., 
2002).  En el caso de la proteína F del RSV bovino, se ha sugerido un papel de 
modulación inmunológica para pep27 (Zimmer y col., 2003), sin embargo dicha 
función no se ha podido atribuir al péptido de RSV humano, que además no 
tiene similitud de secuencia con su homólogo bovino. 
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Las estructuras cristalinas de las formas pre- y postfusión de tres proteínas F 
de los paramixovirus se han resuelto recientemente, mostrando diferencias 
conformacionales sustanciales entre ambas estructuras (Swanson y col., 2010; 
Yin y col., 2005; 2006).  Se han modelado las estructuras tridimensionales de 
las formas pre- y postfusión de la proteína F de RSV a partir de las estructuras 
publicadas de la forma prefusión del HPIV5 (Fig. 1.4B) y la forma postfusión del 
HPIV3 (1.4.C). La forma global de la estructura prefusión es la de una cabeza 
globular unida a un tallo cilíndrico formado por una triple hélice superenrollada 
que contiene las regiones HRB. La cabeza globular está formada por las 
regiones HRA y por el péptido de fusión, que está escondido entre las 
subunidades de la cabeza globular.  La localización del péptido de fusión se 
asemeja a la de la estructura prefusión del virus de la influenza HA (Skehel y 
Wiley, 2000).  Aunque su conformación no se conoce, se cree que la región 
glicosilada que se encuentra entre los dos sitios de corte (pep27), forma un 
loop accesible al solvente.  Como se observa en la Fig. 1.4.C, la forma 
postfusión puede relacionarse con la forma prefusión mediante un giro del 
dominio que forma el tallo, respecto de la cabeza.  Durante el proceso de fusión 
(ver sección 8.1.3.3), la región HRA se pliega en una conformación de alfa-
hélice sencilla extendida (coiled coil) que interacciona con los dominios HRB 
para dar lugar a la estructura 6HB postfusión.  
 
8.1.3.2  Proteínas de unión al receptor de paramixovirus 
 
Las proteínas de unión al receptor de los paramixovirus (HN, H, o G, según el 
virus) pueden variar ampliamente en cuanto a su estructura y en cuanto al 
receptor al cual se unen.  El virus Sendai, junto con otros miembros de los 
géneros Respirovirus y Rubulavirus, posee una proteína de unión con actividad 
hemaglutinina-neuraminidasa (HN).  Se cree que la unión del virus a la célula 
diana tiene lugar mediante la unión de HN a receptores de la membrana celular 
que tienen ácido siálico, mientras que la actividad neuraminidasa de HN podría 
prevenir la agregación entre partículas virales emergentes (revisión en Villar y 
Barroso 2006).  La proteína HN también promueve la fusión, y se requiere la 
co-expresión de proteínas F y HN homotípicas para la fusión de la mayoría de 
los paramixovirus (Horvath y col., 1992). Se ha propuesto que la union de la 
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protein HN al receptor induce cambios conformacionales que activan o 
disponen la proteína F para la fusión (Rusell y col. 2001). 
 
La proteína HN (Figura 1.5) es una proteína integral de membrana de clase II, 
que se compone de una región de anclaje a membrana (TM) que actúa como 
un péptido de señal para dirigir la proteína al retículo endoplásmico durante su 
biosíntesis, un dominio del tallo próximo a la membrana y un dominio con forma 
de cabeza globular C-terminal que contiene las actividades de unión al receptor 
y la actividad de neuraminidasa (Thompson y Portner 1987).  La estructura de 
la cabeza globular (Figura 1.5B) tiene la conformación de propulsor de seis 
láminas o six-blade propeller, típica de otras estructuras de neuraminidasa 
(Crennell y col., 2000; Lawrence y col., 2004).  Inicialmente se pensó que las 
dos actividades se localizaban en el mismo sitio,  sin embargo distintos 
estudios de las proteínas HN de NDV y HPIV3 sugieren la presencia de un 
segundo sitio de unión a ácido siálico en la superficie de interacción entre 
dímeros (Porotto y col. 2006, 2007; Zaitsev  y col. 2004).  Para NDV, se ha 
postulado que la unión de ácido siálico al primer sitio activa el segundo, 
prolongando la unión del virus a la célula diana (Porotto y col. 2006).  
 
La proteína HN forma homotetrámeros a través de la región del tallo (Yuan y 
col., 2005), que también puede interaccionar con la proteína F para promover la 
fusión (ver sección 8.1.3.4).  Estudios que utilizan proteínas HN mutantes han 
demostrado que esta function de la proteína HN como activadora de la proteína 
F reside en el dominio del tallo (Porotto y col., 2003).  Se cree que el equilibro 
entre las propiedades de la HN como proteína de unión al receptor y regulador 
de la activación de F regula la entrada del virus. 
 
La estructura de la proteína de unión al receptor de los neumovirus (G), (Figura 
1.5) difiere ampliamente de la de las proteínas de unión HN de los 
paramixovirus.  La proteína G carece de actividades hemaglutinina y 
neuraminidasa y no se une al ácido siálico.  La proteína G de RSV es una 
proteína integral de membrana de tipo II con un único dominio hidrofóbico que 
funciona como péptido señal y como dominio transmembranal.  La proteína G 
tiene dos dominios altamente glicosilados parecidos a mucina, y migra en SDS-
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PAGE con una movilidad mucho menor que la predicha por su peso molecular, 
debido a su extensa O-glicosilación.  A diferencia de lo que sucede con la 
proteína HN de los paramixovirus, la proteína G de los neumovirus no es 
necesario para la fusión célula-célula o virus-célula (Biacchesi y col., 2004; 
Karron y col., 1997; Schmidt y col., 2002; Schowalter y col., 2006; 
Techaarpornkul y col., 2001, 2002). 
 
Como se muestra en el modelo de la figura 1.5C, se ha sugerido que los dos 
dominios del tipo mucina formen regiones extendidas no plegadas, separadas 
por una región central de 13 aminoácidos que se encuentra conservada y que 
carece de sitios de glicosilación. Esta region contiene cuatro cisteínas 
conservadas que forman dos puentes disulfuro, resultando en un bucle de 
cisteína o cystine noose.  Aunque la region central no es necesaria para la 
replicación eficiente de RSV, puede tener un papel inmunoregulador (Polack y 
col. 2005). Un segmento corto adyacente al bucle de cisteínas se ha 
identificado como un dominio de union a heparina (HBD), que facilita la unión 
de la protein G a los glicosaminoglicanos (GAGs) de la superficie celular.  
 
La proteína G se produce en dos formas (i) una proteína transmembranal de 
tipo II (Gm), que se incorpora a la envuelta del virión a través de una region 
hidrofóbica cercana al extremo N-terminal, y (ii) una proteína soluble (Gs), que 
se produce por una iniciación alternativa de la traducción, originando una 
proteína sin región de anclaje a la membrana, por lo que es secretada por las 
células infectadas. Mientras que Gm forma homo-oligómeros (probablemente 
tetrámeros), Gs es monomérica, lo que sugiere que la región transmembranal 
es necesaria para la oligomerización (Escribano-Romero y col. 2004).  Aunque 
Gm es responsable de la union a los GAGs de la célula diana durante la 
entrada del virus, se ha propuesto para Gs una function inmunomoduladora o 
como cebo de anticuerpos.  
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8.1.3.3  Modelo de la fusión de membranas de los paramixovirus  
 
Por estudios realizados con péptidos de las regiones heptádicas, se ha 
mostrado que durante los cambios conformacionales que tienen lugar durante 
el proceso de fusión, las regiones HRA y HRB están expuestas antes de que se 
alcance la estructura termoestable final de 6HB (Russell y col., 2001).  La 
obtención posteriormente de la estructura cristalina de las formas pre- y 
posfusión de la proteína F dio lugar a una hipótesis para el mecanismo de 
fusión de membrana que se resume en la figura 1.6 (Yin y col., 2006).  En la 
primera etapa, las hélices HRB se separan desde la base de la cabeza en su 
conformación prefusion (1.6b).  Este intermedio de tallo abierto o open stalk se 
pliega inmediatamente en un intermedio de pre-horquilla o prehairpin, en el cual 
se forma la estructura superhelicoidal (coiled-coil) de las regiones HRA debido 
a la traslocación del péptido de fusión en dirección a la membrana de la célula 
diana (1.6c).  La reestructuración final conduce a la fusión (1.6d), para lo cual la 
región transmembranal y el péptido de fusión quedan insertados en la misma 
membrana (1.6e). 
                                            
8.1.3.4  Función de la proteína de union al receptor en la fusión de los 
paramixovirus  
 
Se ha propuesto un mecanismo por el cual la presencia de HN rebaja la 
energía de activación requerida para la fusión de membranas por la proteína F 
(Paterson y col., 2000).  La interacción entre F y HN se ha demostrado en la 
superficie de células transfectadas (Deng y col., 1999) o infectadas (Stone-
Huslander y Morrison 1997).  Algunos estudios realizados con proteínas HN 
quiméricas sugieren que las regiones del tallo y de la cabeza de HN participan 
en las interacciones con la proteína F (Deng y col., 1995; Tanabayashi y 
Compans 1996; Tsurudome y col., 1995).  Se han propuesto modelos 
alternativos para explicar la manera en la que la proteína HN dispara la 
activación de la proteína F (Connolly y col, 2009).  En el primero (modelo 
“pinza”), HN interacciona con la proteína F para estabilizarla en un estado 
metaestable antes de unirse a la célula diana.  Los cambios conformacionales 
que sufre la protein HN a causa de su union al ácido siálico de la célula 
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producen la liberación de la proteína F.  Según un modelo alternativo (modelo 
“provocador”) son los cambios conformacionales sufridos por HN tras su unión 
al receptor los que desencadenan la fusión por la desestabilización de la 
proteína F.  De acuerdo con el segundo modelo, la interacción entre HN y F 
podría ocurrir antes o después de la unión al receptor. Sin embargo, la 
naturaleza de los cambios conformacionales que sufre HN y su efecto sobre la 
proteína F aún no se han determinado.  
 
Mientras que la proteína F de SeV, junto con la mayoría de los miembros de la 
subfamilia Paramyxoviridae requiere co-expresión de la proteína de unión HN 
para fusionar células en cultivo, F_RSV
 
es capaz de fusionar membranas en 
ausencia
 
de la proteína de unión G.  Mutantes espontáneos o recombinantes 
de RSV manipulados genéticamente que expresan F como única glicoproteína 
de superficie son capaces de infectar células y formar sincitios (Karron y col., 
1997; Schmidt y col., 2002; Techaarpornkul y col., 2001, 2002).  Por otro lado, 
la expresión de la proteína F_RSV
 
como única proteína viral en células 
transfectadas es suficiente para inducir la formación de sincitios (González-
Reyes et al., 2001; Zimmer et al., 2001a).  F_RSV
 
se une a glicosaminoglicanos 
(GAGs) de tipo del heparán sulfato, (Feldman y col., 2000; Techaarpornkul y 
col., 2002), lo que puede representar una interacción inicial no específica que 
permitiría la unión posterior de F_RSV
 
a un receptor específico que active la 
proteína F para la fusión en ausencia de la proteína G (Feldman y col., 2000).  
La proteína F del metaneumovirus humano (HMPV) también induce la 
formación de sincitios en células transfectadas en ausencia de proteína G, 
siendo este proceso dependiente de pH ácido en algunos cepas (Herfst y col., 
2009; Schowalter y col., 2006, 2009).  En definitiva, no se conoce el papel 
exacto de las proteínas de unión al receptor de los miembros de la subfamilia 
Pneumovirinae en el proceso de fusión, pero todo parece indicar que las 
proteínas F de los neumovirus poseen mecanismos alternativos para la unión al 
receptor y la fusión de membranas. 
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Insertion of the Two Cleavage Sites of the Respiratory Syncytial Virus
Fusion Protein in Sendai Virus Fusion Protein Leads to Enhanced
Cell-Cell Fusion and a Decreased Dependency on the
HN Attachment Protein for Activity
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Cell entry by paramyxoviruses requires fusion of the viral envelope with the target cell membrane.
Fusion is mediated by the viral fusion (F) glycoprotein and usually requires the aid of the attachment
glycoprotein (G, H or HN, depending on the virus). Human respiratory syncytial virus F protein (FRSV)
is able to mediate membrane fusion in the absence of the attachment G protein and is unique in possessing
two multibasic furin cleavage sites, separated by a region of 27 amino acids (pep27). Cleavage at both sites
is required for cell-cell fusion. We have investigated the significance of the two cleavage sites and pep27
in the context of Sendai virus F protein (FSeV), which possesses a single monobasic cleavage site and
requires both coexpression of the HN attachment protein and trypsin in order to fuse cells. Inclusion of
both FRSV cleavage sites in FSeV resulted in a dramatic increase in cell-cell fusion activity in the presence
of HN. Furthermore, chimeric FSeV mutants containing both FRSV cleavage sites demonstrated cell-cell
fusion in the absence of HN. The presence of two multibasic cleavage sites may therefore represent a
strategy to regulate activation of a paramyxovirus F protein for cell-cell fusion in the absence of an
attachment protein.
Human respiratory syncytial virus (RSV) and Sendai virus
(SeV) are members of the Pneumovirinae and Paramyxovirinae
subfamilies, respectively, within the Paramyxoviridae family of
negative-stranded RNA viruses (Mononegavirales) (5). Cell en-
try by paramyxoviruses requires fusion of the viral envelope
with the target cell membrane at the cell surface. Paramyxovi-
rus-infected cells are also capable of fusing with adjacent cells
to form syncytia (multinuclear, giant cells). Fusion in both
cases is mediated by viral envelope glycoproteins, namely, the
fusion (F) protein, a trimeric type I integral membrane glyco-
protein.
The F polypeptide is synthesized as an inactive precursor
(F0), which requires proteolytic cleavage to yield fusion-com-
petent, disulfide-linked F2-F1 chains (for a review see refer-
ence 21). Cleavage takes place at either a mono- or multibasic
(RXK/RR) cleavage site, recognized by trypsin- or furin-like
proteases, respectively, immediately upstream of a hydropho-
bic fusion peptide that is inserted into the cell membrane
during fusion (30). Cleavage is an absolute requirement for
fusion, and indeed the nature of the cleavage motif has been
shown to play a role in the pathogenicity of some paramyxo-
viruses (17).
Whereas for most paramyxoviruses, fusion mediated by the
F glycoprotein requires participation of the homotypic attach-
ment protein (G, H, or HN, depending on the virus), the F
protein of human respiratory syncytial virus is able to fuse
membranes in the absence of the attachment G protein. Spon-
taneous mutants (15) or genetically engineered recombinant
RSVs expressing F as the only surface glycoprotein (38, 39) are
able to infect cells and form syncytia. Furthermore, expression
of the RSV F protein as the only viral protein in transfected
cells is sufficient to induce syncytium formation (12, 45).
RSV F protein (FRSV) is unique among the Paramyxoviridae,
since FRSV possesses two furin cleavage sites (site I, RARR109,
and site II, KKRKRR136), which are separated by a region of
27 amino acids (pep27), as shown in Fig. 1A, below. The two
cleavage sites and the length, but not the sequence, of pep27
are highly conserved in all bovine and human RSV strains.
Proteolytic processing at both cleavage sites is required by
FRSV to form syncytia in transfected cells (12, 45). Thus, while
membrane fusion by FRSV does not depend on coexpression of
an attachment protein, there is a requirement for double cleav-
age of the F protein and removal of the intervening pep27,
which is secreted into the medium (28). The function of the
double cleavage and subsequent pep27 removal are currently
unknown, although completion of cleavage is associated with a
change in shape of the RSV F protein (25, 28). An immuno-
modulatory role has been suggested for bovine RSV pep27
(48); however, no such role has been attributed to the human
RSV intervening peptide, which does not share sequence sim-
ilarity with its bovine counterpart.
Despite low sequence identity, paramyxovirus F proteins
share structural elements, including the location of cysteine
residues, hydrophobic domains, and heptad repeats (HR) A
and B, as shown in Fig. 1A, below. Crystallographic data indi-
cate that refolding of the F protein during fusion results in the
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Recombinant Sendai Viruses Expressing Fusion Proteins with Two
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Cell entry by paramyxoviruses requires fusion between viral and cellular membranes. Paramyxovirus
infection also gives rise to the formation of multinuclear, fused cells (syncytia). Both types of fusion are
mediated by the viral fusion (F) protein, which requires proteolytic processing at a basic cleavage site in order
to be active for fusion. In common with most paramyxoviruses, fusion mediated by Sendai virus F protein
(FSeV) requires coexpression of the homologous attachment (hemagglutinin-neuraminidase [HN]) protein,
which binds to cell surface sialic acid receptors. In contrast, respiratory syncytial virus fusion protein (FRSV)
is capable of fusing membranes in the absence of the viral attachment (G) protein. Moreover, FRSV is unique
among paramyxovirus fusion proteins since FRSV possesses two multibasic cleavage sites, which are separated
by an intervening region of 27 amino acids. We have previously shown that insertion of both FRSV cleavage sites
in FSeV decreases dependency on the HN attachment protein for syncytium formation in transfected cells. We
now describe recombinant Sendai viruses (rSeV) that express mutant F proteins containing one or both FRSV
cleavage sites. All cleavage-site mutant viruses displayed reduced thermostability, with double-cleavage-site
mutants exhibiting a hyperfusogenic phenotype in infected cells. Furthermore, insertion of both FRSV cleavage
sites in FSeV reduced dependency on the interaction of HN with sialic acid for infection, thus mimicking the
unique ability of RSV to fuse and infect cells in the absence of a separate attachment protein.
Human respiratory syncytial virus (RSV) and Sendai virus
(SeV) are enveloped, negative-strand RNA viruses that belong
to the Pneumovirinae and Paramyxovirinae subfamilies, respec-
tively, of the Paramyxoviridae (6). Cell entry by paramyxovi-
ruses requires virus binding to target cell receptors, followed by
fusion of the viral envelope with the cellular plasma mem-
brane. Cells infected by paramyxoviruses may also fuse with
adjacent cells to form syncytia (multinucleated cells). Both
virus-cell and cell-cell fusion processes are mediated by the
viral fusion (F) protein, a trimeric type I integral membrane
glycoprotein.
For members of the Paramyxovirinae, including SeV, fusion
mediated by the F glycoprotein requires participation of the
homologous attachment protein (glycoprotein [G], hemagglu-
tinin [H], or hemagglutinin-neuraminidase [HN]). It has been
hypothesized that conformational changes occurring in the at-
tachment protein following binding to target cell receptors are
transduced to the F protein to activate it for fusion “at the right
time and in the right place” (26–28). Sialic acid-containing
gangliosides act as the cellular receptor for the Sendai virus
HN attachment protein (31, 32). While the specific cell surface
receptor for pneumoviruses is unknown, RSV has been shown
to interact with cell surface glycosaminoglycans (GAGs), in
particular, with heparan sulfate (12, 13, 18, 20, 25, 33). Fur-
thermore, the fusion protein of both human and bovine RSV
(BRSV), as well as human metapneumovirus (MPV) is suffi-
cient to mediate attachment and fusion in the absence of the G
attachment protein (2, 16, 21, 43, 44, 47, 48, 52). Thus, the role
of pneumovirus attachment proteins in triggering fusion is
currently unclear. Since RSV F protein (FRSV) also binds to
GAGs, the interaction between FRSV and heparan sulfate on
the target cell surface may mediate virus attachment in the
absence of the G protein (14, 20, 48).
The paramyxovirus F protein is synthesized as an inactive
precursor (F0), which is cleaved at a mono- or multibasic cleav-
age site by cellular proteases to produce a fusion-competent,
disulfide-linked F2-F1 complex (for a review, see reference 28).
Cleavage is an absolute requirement for fusion since the newly
formed F1 N terminus contains a hydrophobic fusion peptide
that is inserted into the cell membrane during fusion (40).
Furthermore, the nature of the cleavage motif is a major de-
terminant of virus pathogenicity (23). Sendai virus F protein
(FSeV) is cleaved at a monobasic cleavage site (R116) and thus
requires the addition of trypsin to fuse cells in culture (22, 42).
In contrast, RSV F protein (FRSV) possesses two conserved
multibasic furin-dependent cleavage sites (site I, RARR109;
site II, KKRKRR136), separated by a region of 27 amino acids
(pep27). The presence of two cleavage sites in FRSV is unique
among paramyxoviruses although two cleavage sites have been
observed in the severe acute respiratory syndrome (SARS)
coronavirus spike protein (1). Interestingly, while cell-cell fu-
sion directed by FRSV does not depend on coexpression of an
attachment protein, there is a requirement for proteolytic pro-
cessing at both cleavage sites, accompanied by removal of the
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